Raras
Buscar doenças, sintomas, genes...
Hemopatia mieloide
Mantido por Agente Raras·Colaborar como especialista →

Introdução

O que você precisa saber de cara

📋

Proteína contendo domínios Ras e EF-hand, também conhecida como proteína relacionada a Ras Rab-45, é uma proteína que em humanos é codificada pelo gene RASEF.

Medicamentos
9 registrados
LENALIDOMIDE, DECITABINE, AZACITIDINE

Tem tratamento?

9 medicamentos registrados
Ver detalhes, fases e interações →
LENALIDOMIDEDECITABINEAZACITIDINELUSPATERCEPTCEDAZURIDINEIDARUBICIN HYDROCHLORIDEGEMTUZUMAB OZOGAMICINSARGRAMOSTIMMIDOSTAURIN
🏥
SUS: Sem cobertura SUSScore: 0%
Você se identifica com essa condição?
O Raras está aqui pra te apoiar — com ou sem diagnóstico

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Entender a doença

Do básico ao detalhe, leia no seu ritmo

Preparando trilha educativa...

Sinais e sintomas

O que aparece no corpo e com que frequência cada sintoma acontece

Partes do corpo afetadas

🩸
Sangue
39 sintomas
🦴
Ossos e articulações
16 sintomas
🫁
Pulmão
7 sintomas
🫃
Digestivo
6 sintomas
🧠
Neurológico
6 sintomas
📏
Crescimento
5 sintomas

+ 95 sintomas em outras categorias

Características mais comuns

Hiperplasia eritroide
Sintoma constitucional
Hepatoesplenomegalia
Fadiga fácil
Neoplasia hematológica
Caquexia
200sintomas
Sem dados (200)

Os sintomas variam de pessoa para pessoa. Abaixo estão as 200 características clínicas mais associadas, ordenadas por frequência.

Hiperplasia eritroideErythroid hyperplasia
Sintoma constitucionalConstitutional symptom
HepatoesplenomegaliaHepatosplenomegaly
Fadiga fácilEasy fatigability
Neoplasia hematológicaHematological neoplasm

Linha do tempo da pesquisa

Publicações por ano — veja quando o interesse científico cresceu
Anos de pesquisa11
Últimos 10 anos77publicações
Pico202311 papers
Linha do tempo
20202015Hoje · 2026🧪 2013Primeiro ensaio clínico📈 2023Ano de pico
Publicações por ano (últimos 10 anos)

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Genética e causas

O que está alterado no DNA e como passa nas famílias

Genes associados

56 genes identificados com associação a esta condição.

MLLT10Protein AF-10Disease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Probably involved in transcriptional regulation. In vitro or as fusion protein with KMT2A/MLL1 has transactivation activity. Binds to cruciform DNA. In cells, binding to unmodified histone H3 regulates DOT1L functions including histone H3 'Lys-79' dimethylation (H3K79me2) and gene activation (PubMed:26439302)

LOCALIZAÇÃO

Nucleus

EXPRESSÃO TECIDUAL(Ubíquo)
Testículo
50.9 TPM
Cervix Ectocervix
32.3 TPM
Útero
31.2 TPM
Ovário
30.5 TPM
Bladder
29.2 TPM
OUTRAS DOENÇAS (2)
acute myeloid leukemiaprecursor T-cell acute lymphoblastic leukemia
HGNC:16063UniProt:P55197
DEKProtein DEKCandidate gene tested inTolerante
FUNÇÃO

Involved in chromatin organization

LOCALIZAÇÃO

Nucleus

VIAS BIOLÓGICAS (3)
Transcriptional regulation by the AP-2 (TFAP2) family of transcription factorsTranscriptional regulation of granulopoiesisB-WICH complex positively regulates rRNA expression
EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
163.2 TPM
Fibroblastos
118.3 TPM
Tireoide
98.6 TPM
Artéria tibial
94.1 TPM
Útero
92.9 TPM
OUTRAS DOENÇAS (1)
acute myeloid leukemia with t(6;9)(p23;q34)
HGNC:2768UniProt:P35659
TBL1XR1F-box-like/WD repeat-containing protein TBL1XR1Candidate gene tested inAltamente restrito
FUNÇÃO

F-box-like protein involved in the recruitment of the ubiquitin/19S proteasome complex to nuclear receptor-regulated transcription units. Plays an essential role in transcription activation mediated by nuclear receptors. Probably acts as integral component of the N-Cor corepressor complex that mediates the recruitment of the 19S proteasome complex, leading to the subsequent proteasomal degradation of N-Cor complex, thereby allowing cofactor exchange, and transcription activation

LOCALIZAÇÃO

Nucleus

VIAS BIOLÓGICAS (10)
PPARA activates gene expressionActivation of gene expression by SREBF (SREBP)Transcriptional regulation of white adipocyte differentiationRORA,B,C and NR1D1 (REV-ERBA) regulate gene expressionExpression of BMAL (ARNTL), CLOCK, and NPAS2
MECANISMO DE DOENÇA

Pierpont syndrome

An autosomal dominant syndrome characterized by multiple congenital anomalies, global developmental delay, learning disability, palmar and plantar fat pads, and distinctive facial characteristics, especially when smiling.

EXPRESSÃO TECIDUAL(Ubíquo)
Tireoide
51.9 TPM
Cervix Ectocervix
38.1 TPM
Cervix Endocervix
37.9 TPM
Fibroblastos
36.7 TPM
Aorta
35.9 TPM
OUTRAS DOENÇAS (3)
Pierpont syndromeintellectual disability, autosomal dominant 41acute promyelocytic leukemia
HGNC:29529UniProt:Q9BZK7
NABP1SOSS complex subunit B2Candidate gene tested inTolerante
FUNÇÃO

Component of the SOSS complex, a multiprotein complex that functions downstream of the MRN complex to promote DNA repair and G2/M checkpoint. In the SOSS complex, acts as a sensor of single-stranded DNA that binds to single-stranded DNA, in particular to polypyrimidines. The SOSS complex associates with DNA lesions and influences diverse endpoints in the cellular DNA damage response including cell-cycle checkpoint activation, recombinational repair and maintenance of genomic stability. Required

LOCALIZAÇÃO

Nucleus

VIAS BIOLÓGICAS (1)
RNA polymerase II transcribes snRNA genes
EXPRESSÃO TECIDUAL(Ubíquo)
Fibroblastos
53.0 TPM
Baço
33.5 TPM
Pulmão
22.1 TPM
Sangue
19.2 TPM
Intestino delgado
16.3 TPM
OUTRAS DOENÇAS (1)
acute promyelocytic leukemia
HGNC:26232UniProt:Q96AH0
PMLProtein PMLCandidate gene tested inRestrito
FUNÇÃO

Functions via its association with PML-nuclear bodies (PML-NBs) in a wide range of important cellular processes, including tumor suppression, transcriptional regulation, apoptosis, senescence, DNA damage response, and viral defense mechanisms. Acts as the scaffold of PML-NBs allowing other proteins to shuttle in and out, a process which is regulated by SUMO-mediated modifications and interactions. Inhibits EIF4E-mediated mRNA nuclear export by reducing EIF4E affinity for the 5' 7-methylguanosine

LOCALIZAÇÃO

NucleusNucleus, nucleoplasmCytoplasmNucleus, PML bodyNucleus, nucleolusEndoplasmic reticulum membraneEarly endosome membrane

VIAS BIOLÓGICAS (1)
Interferon gamma signaling
EXPRESSÃO TECIDUAL(Ubíquo)
Tecido adiposo
55.3 TPM
Útero
50.0 TPM
Cervix Ectocervix
49.5 TPM
Pulmão
49.1 TPM
Mama
49.1 TPM
OUTRAS DOENÇAS (1)
acute promyelocytic leukemia
HGNC:9113UniProt:P29590
MRTFAMyocardin-related transcription factor ACandidate gene tested inAltamente restrito
FUNÇÃO

Transcription coactivator that associates with the serum response factor (SRF) transcription factor to control expression of genes regulating the cytoskeleton during development, morphogenesis and cell migration (PubMed:26224645). The SRF-MRTFA complex activity responds to Rho GTPase-induced changes in cellular globular actin (G-actin) concentration, thereby coupling cytoskeletal gene expression to cytoskeletal dynamics. MRTFA binds G-actin via its RPEL repeats, regulating activity of the MRTFA-

LOCALIZAÇÃO

CytoplasmNucleus

VIAS BIOLÓGICAS (1)
RHO GTPases Activate Formins
OUTRAS DOENÇAS (3)
immunodeficiency 66megakaryoblastic acute myeloid leukemia with t(1;22)(p13;q13)immune deficiency due to impaired neutrophil phagocytosis and migration
HGNC:14334UniProt:Q969V6
STAT5BSignal transducer and activator of transcription 5BCandidate gene tested inAltamente restrito
FUNÇÃO

Carries out a dual function: signal transduction and activation of transcription (PubMed:29844444). Mediates cellular responses to the cytokine KITLG/SCF and other growth factors. Binds to the GAS element and activates PRL-induced transcription. Positively regulates hematopoietic/erythroid differentiation

LOCALIZAÇÃO

CytoplasmNucleus

VIAS BIOLÓGICAS (10)
Prolactin receptor signalingInterleukin-2 signalingErythropoietin activates STAT5Interleukin-7 signalingInterleukin-3, Interleukin-5 and GM-CSF signaling
MECANISMO DE DOENÇA

Growth hormone insensitivity syndrome with immune dysregulation 1, autosomal recessive

An autosomal recessive form of growth hormone insensitivity syndrome, a congenital disease characterized by short stature, growth hormone deficiency in the presence of normal to elevated circulating concentrations of growth hormone, resistance to exogeneous growth hormone therapy, and recurrent infections. Most, but not all, patients have features of immune dysregulation.

EXPRESSÃO TECIDUAL(Ubíquo)
Útero
155.5 TPM
Sangue
138.5 TPM
Fallopian Tube
134.4 TPM
Ovário
129.2 TPM
Cervix Ectocervix
113.3 TPM
OUTRAS DOENÇAS (3)
growth hormone insensitivity with immune dysregulation 1, autosomal recessivegrowth hormone insensitivity syndrome with immune dysregulation 2, autosomal dominantacute promyelocytic leukemia
HGNC:11367UniProt:P51692
RUNX1T1Protein CBFA2T1Candidate gene tested inAltamente restrito
FUNÇÃO

Transcriptional corepressor which facilitates transcriptional repression via its association with DNA-binding transcription factors and recruitment of other corepressors and histone-modifying enzymes (PubMed:10688654, PubMed:12559562, PubMed:15203199). Can repress the expression of MMP7 in a ZBTB33-dependent manner (PubMed:23251453). Can repress transactivation mediated by TCF12 (PubMed:16803958). Acts as a negative regulator of adipogenesis (By similarity). The AML1-MTG8/ETO fusion protein freq

LOCALIZAÇÃO

Nucleus

EXPRESSÃO TECIDUAL(Ubíquo)
Cérebro - Hemisfério cerebelar
37.2 TPM
Cerebelo
28.5 TPM
Nervo tibial
14.2 TPM
Cervix Ectocervix
12.1 TPM
Cervix Endocervix
11.9 TPM
OUTRAS DOENÇAS (1)
acute myeloid leukemia with t(8;21)(q22;q22) translocation
HGNC:1535UniProt:Q06455
CBFBCore-binding factor subunit betaCandidate gene tested inAltamente restrito
FUNÇÃO

Forms the heterodimeric complex core-binding factor (CBF) with RUNX family proteins (RUNX1, RUNX2, and RUNX3). RUNX members modulate the transcription of their target genes through recognizing the core consensus binding sequence 5'-TGTGGT-3', or very rarely, 5'-TGCGGT-3', within their regulatory regions via their runt domain, while CBFB is a non-DNA-binding regulatory subunit that allosterically enhances the sequence-specific DNA-binding capacity of RUNX. The heterodimers bind to the core site o

LOCALIZAÇÃO

Nucleus

VIAS BIOLÓGICAS (10)
RUNX3 Regulates Immune Response and Cell MigrationRegulation of RUNX3 expression and activityRUNX3 regulates p14-ARFRUNX3 regulates RUNX1-mediated transcriptionTranscriptional regulation by RUNX2
OUTRAS DOENÇAS (2)
cleidocranial dysplasia 2acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)
HGNC:1539UniProt:Q13951
MYH11Myosin-11Candidate gene tested inAltamente restrito
FUNÇÃO

Muscle contraction

LOCALIZAÇÃO

Melanosome

VIAS BIOLÓGICAS (8)
RHO GTPases activate PAKsRHO GTPases Activate ROCKsRHO GTPases activate PKNsRHO GTPases activate CITSema4D induced cell migration and growth-cone collapse
EXPRESSÃO TECIDUAL(Ubíquo)
Esôfago - Muscular
8417.6 TPM
Cólon sigmoide
7101.3 TPM
Esôfago - Junção
6634.6 TPM
Artéria tibial
5189.9 TPM
Bladder
3106.5 TPM
OUTRAS DOENÇAS (7)
megacystis-microcolon-intestinal hypoperistalsis syndrome 2visceral myopathy 2aortic aneurysm, familial thoracic 4acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)
HGNC:7569UniProt:P35749
BCORBCL-6 corepressorCandidate gene tested inAltamente restrito
FUNÇÃO

Transcriptional corepressor. May specifically inhibit gene expression when recruited to promoter regions by sequence-specific DNA-binding proteins such as BCL6 and MLLT3. This repression may be mediated at least in part by histone deacetylase activities which can associate with this corepressor. Involved in the repression of TFAP2A; impairs binding of BCL6 and KDM2B to TFAP2A promoter regions. Via repression of TFAP2A acts as a negative regulator of osteo-dentiogenic capacity in adult stem cells

LOCALIZAÇÃO

Nucleus

MECANISMO DE DOENÇA

Microphthalmia, syndromic, 2

A very rare multiple congenital anomaly syndrome characterized by eye anomalies (congenital cataract, microphthalmia, or secondary glaucoma), facial abnormalities (long narrow face, high nasal bridge, pointed nose with cartilages separated at the tip, cleft palate, or submucous cleft palate), cardiac anomalies (atrial septal defect, ventricular septal defect, or floppy mitral valve) and dental abnormalities (canine radiculomegaly, delayed dentition, oligodontia, persistent primary teeth, or variable root length). Microphthalmia is a disorder of eye formation, ranging from small size of a single eye to complete bilateral absence of ocular tissues (anophthalmia). In many cases, microphthalmia/anophthalmia occurs in association with syndromes that include non-ocular abnormalities.

OUTRAS DOENÇAS (4)
microphthalmia, syndromic 2acute promyelocytic leukemiaclear cell sarcoma of kidneymicrophthalmia, Lenz type
HGNC:20893UniProt:Q6W2J9
TGM6Protein-glutamine gamma-glutamyltransferase 6Candidate gene tested inTolerante
FUNÇÃO

Catalyzes the cross-linking of proteins and the conjugation of polyamines to proteins

LOCALIZAÇÃO

Cytoplasm

MECANISMO DE DOENÇA

Spinocerebellar ataxia 35

A form of spinocerebellar ataxia, a clinically and genetically heterogeneous group of cerebellar disorders. Patients show progressive incoordination of gait and often poor coordination of hands, speech and eye movements, due to degeneration of the cerebellum with variable involvement of the brainstem and spinal cord. SCA35 patients commonly show upper limb involvement and torticollis. There is no cognitive impairment.

EXPRESSÃO TECIDUAL(Não detectado)
Cervix Ectocervix
0.0 TPM
Testículo
0.0 TPM
Skin Sun Exposed Lower leg
0.0 TPM
Skin Not Sun Exposed Suprapubic
0.0 TPM
Esôfago - Mucosa
0.0 TPM
INTERAÇÕES PROTEICAS (1)
OUTRAS DOENÇAS (2)
spinocerebellar ataxia type 35inherited acute myeloid leukemia
HGNC:16255UniProt:O95932
RBM15RNA-binding protein 15Candidate gene tested inAltamente restrito
FUNÇÃO

RNA-binding protein that acts as a key regulator of N6-methyladenosine (m6A) methylation of RNAs, thereby regulating different processes, such as hematopoietic cell homeostasis, alternative splicing of mRNAs and X chromosome inactivation mediated by Xist RNA (PubMed:27602518). Associated component of the WMM complex, a complex that mediates N6-methyladenosine (m6A) methylation of RNAs, a modification that plays a role in the efficiency of mRNA splicing and RNA processing (By similarity). Plays a

LOCALIZAÇÃO

Nucleus speckleNucleus, nucleoplasmNucleus envelopeNucleus membrane

EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
21.8 TPM
Testículo
12.1 TPM
Fibroblastos
7.6 TPM
Baço
6.8 TPM
Pulmão
6.5 TPM
OUTRAS DOENÇAS (1)
megakaryoblastic acute myeloid leukemia with t(1;22)(p13;q13)
HGNC:14959UniProt:Q96T37
KMT2AHistone-lysine N-methyltransferase 2ACandidate gene tested inAltamente restrito
FUNÇÃO

Histone methyltransferase that plays an essential role in early development and hematopoiesis (PubMed:12453419, PubMed:15960975, PubMed:19187761, PubMed:19556245, PubMed:20677832, PubMed:21220120, PubMed:26886794). Catalytic subunit of the MLL1/MLL complex, a multiprotein complex that mediates both methylation of 'Lys-4' of histone H3 (H3K4me) complex and acetylation of 'Lys-16' of histone H4 (H4K16ac) (PubMed:12453419, PubMed:15960975, PubMed:19187761, PubMed:19556245, PubMed:20677832, PubMed:2

LOCALIZAÇÃO

Nucleus

VIAS BIOLÓGICAS (5)
Phosphorylated BMAL1:CLOCK (ARNTL:CLOCK) activates expression of core clock genesRUNX1 regulates transcription of genes involved in differentiation of HSCsPhosphorylation of CLOCK, acetylation of BMAL1 (ARNTL) at target gene promotersThe CRY:PER:kinase complex represses transactivation by the BMAL:CLOCK (ARNTL:CLOCK) complexTranscriptional regulation of granulopoiesis
MECANISMO DE DOENÇA

Wiedemann-Steiner syndrome

A syndrome characterized by hairy elbows (hypertrichosis cubiti), intellectual disability, a distinctive facial appearance, and short stature. Facial characteristics include long eyelashes, thick or arched eyebrows with a lateral flare, and downslanting and vertically narrow palpebral fissures.

EXPRESSÃO TECIDUAL(Ubíquo)
Cerebelo
34.8 TPM
Cérebro - Hemisfério cerebelar
32.5 TPM
Ovário
26.9 TPM
Artéria tibial
25.5 TPM
Útero
24.7 TPM
OUTRAS DOENÇAS (7)
Wiedemann-Steiner syndromemixed phenotype acute leukemia with t(9;22)(q34.1;q11.2)mixed phenotype acute leukemia with t(v;11q23.3)B-lymphoblastic leukemia/lymphoma with t(v;11q23.3)
HGNC:7132UniProt:Q03164
KAT6AHistone acetyltransferase KAT6ACandidate gene tested inAltamente restrito
FUNÇÃO

Histone acetyltransferase that acetylates lysine residues in histone H3 and histone H4 (in vitro) (PubMed:11742995, PubMed:11965546). Component of the MOZ/MORF complex which has a histone H3 acetyltransferase activity (PubMed:11965546). May act as a transcriptional coactivator for RUNX1 and RUNX2 (PubMed:12771199). Acetylates p53/TP53 at 'Lys-120' and 'Lys-382' and controls its transcriptional activity via association with PML (PubMed:23431171). May play a role in leukemogenic gene transcription

LOCALIZAÇÃO

NucleusNucleus, nucleolusNucleus, nucleoplasmNucleus, PML body

VIAS BIOLÓGICAS (2)
Regulation of TP53 Activity through AcetylationHATs acetylate histones
EXPRESSÃO TECIDUAL(Ubíquo)
Pulmão
28.6 TPM
Útero
26.8 TPM
Cervix Ectocervix
25.7 TPM
Skin Sun Exposed Lower leg
25.1 TPM
Nervo tibial
24.6 TPM
OUTRAS DOENÇAS (2)
autosomal dominant intellectual disability-craniofacial anomalies-cardiac defects syndromeacute myeloid leukemia with t(8;16)(p11;p13) translocation
HGNC:13013UniProt:Q92794
CREBBPCREB-binding proteinCandidate gene tested inAltamente restrito
FUNÇÃO

Acetylates histones, giving a specific tag for transcriptional activation (PubMed:21131905, PubMed:24616510). Mediates acetylation of histone H3 at 'Lys-18' and 'Lys-27' (H3K18ac and H3K27ac, respectively) (PubMed:21131905). Also acetylates non-histone proteins, like DDX21, FBL, IRF2, MAFG, NCOA3, POLR1E/PAF53 and FOXO1 (PubMed:10490106, PubMed:11154691, PubMed:12738767, PubMed:12929931, PubMed:24207024, PubMed:28790157, PubMed:30540930, PubMed:35675826, PubMed:9707565). Binds specifically to ph

LOCALIZAÇÃO

CytoplasmNucleus

VIAS BIOLÓGICAS (1)
SARS-CoV-2 activates/modulates innate and adaptive immune responses
EXPRESSÃO TECIDUAL(Ubíquo)
Útero
53.4 TPM
Ovário
49.6 TPM
Cervix Endocervix
48.1 TPM
Cerebelo
45.0 TPM
Artéria tibial
41.8 TPM
OUTRAS DOENÇAS (5)
Menke-Hennekam syndrome 1Rubinstein-Taybi syndrome due to CREBBP mutationsMenke-Hennekam syndromeacute myeloid leukemia with t(8;16)(p11;p13) translocation
HGNC:2348UniProt:Q92793
ZBTB16Zinc finger and BTB domain-containing protein 16Candidate gene tested inAltamente restrito
FUNÇÃO

Acts as a transcriptional repressor (PubMed:10688654, PubMed:24359566). Transcriptional repression may be mediated through recruitment of histone deacetylases to target promoters (PubMed:10688654). May play a role in myeloid maturation and in the development and/or maintenance of other differentiated tissues. Probable substrate-recognition component of an E3 ubiquitin-protein ligase complex which mediates the ubiquitination and subsequent proteasomal degradation of target proteins (PubMed:145283

LOCALIZAÇÃO

NucleusNucleus, nuclear body

VIAS BIOLÓGICAS (2)
Antigen processing: Ubiquitination & Proteasome degradationNeddylation
MECANISMO DE DOENÇA

Skeletal defects, genital hypoplasia, and impaired intellectual development

A disorder characterized by intellectual disability, craniofacial dysmorphism, microcephaly and short stature. Additional features include absence of the thumbs, hypoplasia of the radii and ulnae, additional vertebrae and ribs, retarded bone age and genital hypoplasia.

EXPRESSÃO TECIDUAL(Ubíquo)
Artéria tibial
112.3 TPM
Aorta
71.4 TPM
Tecido adiposo
61.8 TPM
Nervo tibial
57.0 TPM
Artéria coronária
54.9 TPM
OUTRAS DOENÇAS (2)
acute promyelocytic leukemiaprecursor T-cell acute lymphoblastic leukemia
HGNC:12930UniProt:Q05516
NUMA1Nuclear mitotic apparatus protein 1Candidate gene tested inAltamente restrito
FUNÇÃO

Microtubule (MT)-binding protein that plays a role in the formation and maintenance of the spindle poles and the alignement and the segregation of chromosomes during mitotic cell division (PubMed:17172455, PubMed:19255246, PubMed:24996901, PubMed:26195665, PubMed:27462074, PubMed:7769006). Functions to tether the minus ends of MTs at the spindle poles, which is critical for the establishment and maintenance of the spindle poles (PubMed:11956313, PubMed:12445386). Plays a role in the establishmen

LOCALIZAÇÃO

NucleusNucleus, nucleoplasmNucleus matrixChromosomeCytoplasm, cytoskeletonCytoplasm, cytoskeleton, microtubule organizing center, centrosomeCytoplasm, cytoskeleton, spindle poleCytoplasm, cell cortexCell membraneLateral cell membraneCytoplasm, cytosol

VIAS BIOLÓGICAS (1)
Mitotic Prophase
EXPRESSÃO TECIDUAL(Ubíquo)
Cervix Ectocervix
145.1 TPM
Cervix Endocervix
144.4 TPM
Útero
143.8 TPM
Ovário
130.7 TPM
Próstata
130.3 TPM
OUTRAS DOENÇAS (1)
acute promyelocytic leukemia
HGNC:8059UniProt:Q14980
FIP1L1Pre-mRNA 3'-end-processing factor FIP1Candidate gene tested inAltamente restrito
FUNÇÃO

Component of the cleavage and polyadenylation specificity factor (CPSF) complex that plays a key role in pre-mRNA 3'-end formation, recognizing the AAUAAA signal sequence and interacting with poly(A) polymerase and other factors to bring about cleavage and poly(A) addition. FIP1L1 contributes to poly(A) site recognition and stimulates poly(A) addition. Binds to U-rich RNA sequence elements surrounding the poly(A) site. May act to tether poly(A) polymerase to the CPSF complex

LOCALIZAÇÃO

Nucleus

VIAS BIOLÓGICAS (6)
mRNA 3'-end processingDengue Virus-Host InteractionsTransport of Mature mRNA Derived from an Intronless TranscriptProcessing of Intronless Pre-mRNAsRNA Polymerase II Transcription Termination
EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
79.7 TPM
Testículo
78.1 TPM
Fibroblastos
70.5 TPM
Ovário
55.4 TPM
Cervix Endocervix
47.6 TPM
OUTRAS DOENÇAS (3)
acute promyelocytic leukemiaprimary hypereosinophilic syndromechronic eosinophilic leukemia
HGNC:19124UniProt:Q6UN15
STAT3Signal transducer and activator of transcription 3Candidate gene tested inAltamente restrito
FUNÇÃO

Signal transducer and transcription activator that mediates cellular responses to interleukins, KITLG/SCF, LEP and other growth factors (PubMed:10688651, PubMed:12359225, PubMed:12873986, PubMed:15194700, PubMed:15653507, PubMed:16285960, PubMed:17344214, PubMed:18242580, PubMed:18782771, PubMed:22306293, PubMed:23084476, PubMed:28262505, PubMed:32929201, PubMed:38404237). Once activated, recruits coactivators, such as NCOA1 or MED1, to the promoter region of the target gene (PubMed:15653507, Pu

LOCALIZAÇÃO

CytoplasmNucleus

VIAS BIOLÓGICAS (10)
Interleukin-20 family signalingDownstream signal transductionInterleukin-15 signalingSignaling by SCF-KITInterleukin-9 signaling
MECANISMO DE DOENÇA

Hyper-IgE syndrome 1, autosomal dominant, with recurrent infections

A rare disorder of immunity and connective tissue characterized by immunodeficiency, chronic eosinophilia, distinctive coarse facial appearance, abnormal dentition, hyperextensibility of the joints, and bone fractures.

EXPRESSÃO TECIDUAL(Ubíquo)
Pulmão
173.0 TPM
Artéria tibial
145.7 TPM
Aorta
144.8 TPM
Adipose Visceral Omentum
140.2 TPM
Fallopian Tube
136.9 TPM
OUTRAS DOENÇAS (7)
hyper-IgE recurrent infection syndrome 1, autosomal dominantSTAT3-related early-onset multisystem autoimmune diseasebreast implant-associated anaplastic large cell lymphomaacute promyelocytic leukemia
HGNC:11364UniProt:P40763
ERCC6L2DNA excision repair protein ERCC-6-like 2Candidate gene tested inTolerante
FUNÇÃO

Promotes double-strand break (DSB) end-joining and facilitates programmed recombination by controlling how DNA ends are joined in a spatially oriented manner during repair (By similarity). Also plays a role in DNA repair by restricting DNA end resection in double strand break (DSB) repair (PubMed:24507776, PubMed:37014751). Facilitates replication of complex DNA regions and regulates the maintenance of chromatin structure (PubMed:37014751)

LOCALIZAÇÃO

NucleusCytoplasm, cytoskeleton, microtubule organizing center, centrosomeMitochondrionChromosome, centromere

MECANISMO DE DOENÇA

Bone marrow failure syndrome 2

An autosomal recessive disorder characterized by trilineage bone marrow failure, bone marrow hypocellularity, learning difficulties, and microcephaly. Insufficient hematopoiesis results in peripheral blood cytopenias, affecting myeloid, erythroid and megakaryocyte lines. Cutaneous features and increased chromosome breakage are not features.

EXPRESSÃO TECIDUAL(Ubíquo)
Nervo tibial
8.8 TPM
Cervix Ectocervix
7.6 TPM
Cervix Endocervix
7.4 TPM
Ovário
7.2 TPM
Útero
6.6 TPM
INTERAÇÕES PROTEICAS (1)
OUTRAS DOENÇAS (2)
pancytopenia-developmental delay syndromeinherited acute myeloid leukemia
HGNC:26922UniProt:Q5T890
CBFA2T3Transcriptional corepressor CBFA2T3Candidate gene tested inTolerante
FUNÇÃO

Transcriptional corepressor which facilitates transcriptional repression via its association with DNA-binding transcription factors and recruitment of other corepressors and histone-modifying enzymes (PubMed:12559562, PubMed:15203199, PubMed:16966434, PubMed:18456661). Can repress the expression of MMP7 in a ZBTB33-dependent manner (PubMed:23251453). Reduces the protein levels and stability of the transcriptinal regulator HIF1A; interacts with EGLN1 and promotes the HIF1A prolyl hydroxylation-de

LOCALIZAÇÃO

NucleusNucleus, nucleolusNucleus, nucleoplasmGolgi apparatus membrane

OUTRAS DOENÇAS (1)
acute megakaryoblastic leukemia without down syndrome
HGNC:1537UniProt:O75081
PDGFRBPlatelet-derived growth factor receptor betaCandidate gene tested inAltamente restrito
FUNÇÃO

Tyrosine-protein kinase that acts as a cell-surface receptor for homodimeric PDGFB and PDGFD and for heterodimers formed by PDGFA and PDGFB, and plays an essential role in the regulation of embryonic development, cell proliferation, survival, differentiation, chemotaxis and migration. Plays an essential role in blood vessel development by promoting proliferation, migration and recruitment of pericytes and smooth muscle cells to endothelial cells. Plays a role in the migration of vascular smooth

LOCALIZAÇÃO

Cell membraneCytoplasmic vesicleLysosome lumen

VIAS BIOLÓGICAS (1)
Signaling by PDGF
EXPRESSÃO TECIDUAL(Ubíquo)
Cervix Ectocervix
398.1 TPM
Cervix Endocervix
353.6 TPM
Artéria tibial
346.2 TPM
Tecido adiposo
303.2 TPM
Artéria coronária
277.8 TPM
OUTRAS DOENÇAS (10)
myofibromatosis, infantile, 1acroosteolysis-keloid-like lesions-premature aging syndromebasal ganglia calcification, idiopathic, 4ocular pterygium-digital keloid dysplasia syndrome
HGNC:8804UniProt:P09619
TP53Cellular tumor antigen p53Candidate gene tested inAltamente restrito
FUNÇÃO

Multifunctional transcription factor that induces cell cycle arrest, DNA repair or apoptosis upon binding to its target DNA sequence (PubMed:11025664, PubMed:12524540, PubMed:12810724, PubMed:15186775, PubMed:15340061, PubMed:17317671, PubMed:17349958, PubMed:19556538, PubMed:20673990, PubMed:20959462, PubMed:22726440, PubMed:24051492, PubMed:24652652, PubMed:35618207, PubMed:36634798, PubMed:38653238, PubMed:9840937). Acts as a tumor suppressor in many tumor types; induces growth arrest or apop

LOCALIZAÇÃO

CytoplasmNucleusNucleus, PML bodyEndoplasmic reticulumMitochondrion matrixCytoplasm, cytoskeleton, microtubule organizing center, centrosome

VIAS BIOLÓGICAS (10)
TP53 Regulates Metabolic GenesRegulation of TP53 ExpressionRegulation of TP53 DegradationOncogene Induced SenescenceOxidative Stress Induced Senescence
EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
73.0 TPM
Skin Sun Exposed Lower leg
37.0 TPM
Skin Not Sun Exposed Suprapubic
35.2 TPM
Fibroblastos
32.9 TPM
Ovário
32.4 TPM
OUTRAS DOENÇAS (29)
Li-Fraumeni syndromenasopharyngeal carcinoma, susceptibility to, 1hepatocellular carcinomafamilial pancreatic carcinoma
HGNC:11998UniProt:P04637
PRKAR1AcAMP-dependent protein kinase type I-alpha regulatory subunitCandidate gene tested inAltamente restrito
FUNÇÃO

Regulatory subunit of the cAMP-dependent protein kinases involved in cAMP signaling in cells

LOCALIZAÇÃO

Cell membrane

VIAS BIOLÓGICAS (10)
PKA activationGPER1 signalingCREB1 phosphorylation through the activation of Adenylate CyclaseDARPP-32 eventsHigh laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells
MECANISMO DE DOENÇA

Carney complex 1

CNC is a multiple neoplasia syndrome characterized by spotty skin pigmentation, cardiac and other myxomas, endocrine tumors, and psammomatous melanotic schwannomas.

EXPRESSÃO TECIDUAL(Ubíquo)
Artéria tibial
152.7 TPM
Ovário
151.5 TPM
Aorta
138.6 TPM
Útero
138.3 TPM
Tecido adiposo
129.4 TPM
OUTRAS DOENÇAS (9)
familial atrial myxomapigmented nodular adrenocortical disease, primary, 1Acrodysostosis 1 with or without hormone resistanceCarney complex, type 1
HGNC:9388UniProt:P10644
BCRBreakpoint cluster region proteinCandidate gene tested inRestrito
FUNÇÃO

Protein with a unique structure having two opposing regulatory activities toward small GTP-binding proteins. The C-terminus is a GTPase-activating protein (GAP) domain which stimulates GTP hydrolysis by RAC1, RAC2 and CDC42. Accelerates the intrinsic rate of GTP hydrolysis of RAC1 or CDC42, leading to down-regulation of the active GTP-bound form (PubMed:17116687, PubMed:1903516, PubMed:7479768). The central Dbl homology (DH) domain functions as guanine nucleotide exchange factor (GEF) that modul

LOCALIZAÇÃO

Postsynaptic densityCell projection, dendritic spineCell projection, axonSynapse

VIAS BIOLÓGICAS (7)
RAC3 GTPase cycleRHOB GTPase cycleRAC1 GTPase cycleRAC2 GTPase cycleCDC42 GTPase cycle
MECANISMO DE DOENÇA

Leukemia, chronic myeloid

A clonal myeloproliferative disorder of a pluripotent stem cell with a specific cytogenetic abnormality, the Philadelphia chromosome (Ph), involving myeloid, erythroid, megakaryocytic, B-lymphoid, and sometimes T-lymphoid cells, but not marrow fibroblasts.

OUTRAS DOENÇAS (4)
chronic myelogenous leukemia, BCR-ABL1 positivechromosome 22q11.2 deletion syndrome, distalB-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2)precursor T-cell acute lymphoblastic leukemia
HGNC:1014UniProt:P11274
LPPLipoma-preferred partnerDisease-causing germline mutation(s) inTolerante
FUNÇÃO

May play a structural role at sites of cell adhesion in maintaining cell shape and motility. In addition to these structural functions, it may also be implicated in signaling events and activation of gene transcription. May be involved in signal transduction from cell adhesion sites to the nucleus allowing successful integration of signals arising from soluble factors and cell-cell adhesion sites. Also suggested to serve as a scaffold protein upon which distinct protein complexes are assembled i

LOCALIZAÇÃO

NucleusCytoplasmCell junctionCell membrane

VIAS BIOLÓGICAS (1)
Lysosphingolipid and LPA receptors
EXPRESSÃO TECIDUAL(Ubíquo)
Artéria tibial
190.8 TPM
Esôfago - Muscular
147.3 TPM
Aorta
128.2 TPM
Esôfago - Junção
116.1 TPM
Cólon sigmoide
98.3 TPM
INTERAÇÕES PROTEICAS (4)
OUTRAS DOENÇAS (1)
acute myeloid leukemia
HGNC:HGNC:6679UniProt:Q93052
CBLE3 ubiquitin-protein ligase CBLDisease-causing germline mutation(s) inRestrito
FUNÇÃO

E3 ubiquitin-protein ligase that acts as a negative regulator of many signaling pathways by mediating ubiquitination of cell surface receptors (PubMed:10514377, PubMed:11896602, PubMed:14661060, PubMed:14739300, PubMed:15190072, PubMed:17509076, PubMed:18374639, PubMed:19689429, PubMed:21596750, PubMed:28381567, PubMed:40101708). Accepts ubiquitin from specific E2 ubiquitin-conjugating enzymes, and then transfers it to substrates promoting their degradation by the proteasome (PubMed:10514377, Pu

LOCALIZAÇÃO

CytoplasmCell membraneCell projection, ciliumGolgi apparatus

VIAS BIOLÓGICAS (10)
TGF-beta receptor signaling activates SMADsPTK6 Regulates RTKs and Their Effectors AKT1 and DOK1Spry regulation of FGF signalingEGFR downregulationNegative regulation of MET activity
MECANISMO DE DOENÇA

Noonan syndrome-like disorder with or without juvenile myelomonocytic leukemia

A syndrome characterized by a phenotype reminiscent of Noonan syndrome. Clinical features are highly variable, including facial dysmorphism, short neck, developmental delay, hyperextensible joints and thorax abnormalities with widely spaced nipples. The facial features consist of triangular face with hypertelorism, large low-set ears, ptosis, and flat nasal bridge. Some patients manifest cardiac defects. Some have an increased risk for certain malignancies, particularly juvenile myelomonocytic leukemia.

OUTRAS DOENÇAS (4)
CBL-related disorderjuvenile myelomonocytic leukemiaNoonan syndromeaggressive systemic mastocytosis
HGNC:1541UniProt:P22681
SRCProto-oncogene tyrosine-protein kinase SrcDisease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Non-receptor protein tyrosine kinase which is activated following engagement of many different classes of cellular receptors including immune response receptors, integrins and other adhesion receptors, receptor protein tyrosine kinases, G protein-coupled receptors as well as cytokine receptors (PubMed:34234773). Participates in signaling pathways that control a diverse spectrum of biological activities including gene transcription, immune response, cell adhesion, cell cycle progression, apoptosi

LOCALIZAÇÃO

Cell membraneMitochondrion inner membraneNucleusCytoplasm, cytoskeletonCytoplasm, perinuclear regionCell junction, focal adhesionCell junction

VIAS BIOLÓGICAS (3)
G alpha (s) signalling eventsG alpha (i) signalling eventsSignaling by CSF1 (M-CSF) in myeloid cells
EXPRESSÃO TECIDUAL(Ubíquo)
Útero
59.3 TPM
Testículo
55.3 TPM
Bladder
52.0 TPM
Próstata
51.5 TPM
Cervix Ectocervix
49.8 TPM
OUTRAS DOENÇAS (2)
colorectal cancerthrombocytopenia 6
HGNC:11283UniProt:P12931
DNMT3ADNA (cytosine-5)-methyltransferase 3ADisease-causing germline mutation(s) inTolerante
FUNÇÃO

Required for genome-wide de novo methylation and is essential for the establishment of DNA methylation patterns during development (PubMed:12138111, PubMed:16357870, PubMed:30478443). DNA methylation is coordinated with methylation of histones (PubMed:12138111, PubMed:16357870, PubMed:30478443). It modifies DNA in a non-processive manner and also methylates non-CpG sites (PubMed:12138111, PubMed:16357870, PubMed:30478443). May preferentially methylate DNA linker between 2 nucleosomal cores and i

LOCALIZAÇÃO

NucleusChromosomeCytoplasm

VIAS BIOLÓGICAS (6)
RMTs methylate histone argininesDefective pyroptosisPRC2 methylates histones and DNADNA methylationRegulation of endogenous retroelements by Piwi-interacting RNAs (piRNAs)
MECANISMO DE DOENÇA

Tatton-Brown-Rahman syndrome

An overgrowth syndrome characterized by a distinctive facial appearance, tall stature and intellectual disability. Facial gestalt is characterized by a round face, heavy horizontal eyebrows and narrow palpebral fissures. Less common features include atrial septal defects, seizures, umbilical hernia, and scoliosis.

EXPRESSÃO TECIDUAL(Ubíquo)
Cerebelo
20.9 TPM
Cérebro - Hemisfério cerebelar
18.9 TPM
Pituitária
18.8 TPM
Ovário
18.3 TPM
Linfócitos
15.5 TPM
OUTRAS DOENÇAS (5)
Tatton-Brown-Rahman overgrowth syndromeHeyn-Sproul-Jackson syndromeacute myeloid leukemiaacute myeloid leukemia with multilineage dysplasia
HGNC:2978UniProt:Q9Y6K1
PICALMPhosphatidylinositol-binding clathrin assembly proteinDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Cytoplasmic adapter protein that plays a critical role in clathrin-mediated endocytosis which is important in processes such as internalization of cell receptors, synaptic transmission or removal of apoptotic cells. Recruits AP-2 and attaches clathrin triskelions to the cytoplasmic side of plasma membrane leading to clathrin-coated vesicles (CCVs) assembly (PubMed:10436022, PubMed:16262731, PubMed:27574975). Furthermore, regulates clathrin-coated vesicle size and maturation by directly sensing a

LOCALIZAÇÃO

Cell membraneMembrane, clathrin-coated pitGolgi apparatusCytoplasmic vesicle, clathrin-coated vesicleNucleus

VIAS BIOLÓGICAS (3)
Clathrin-mediated endocytosisCargo recognition for clathrin-mediated endocytosisRND3 GTPase cycle
EXPRESSÃO TECIDUAL(Ubíquo)
Artéria tibial
255.3 TPM
Tecido adiposo
210.5 TPM
Aorta
194.4 TPM
Artéria coronária
182.9 TPM
Nervo tibial
175.8 TPM
OUTRAS DOENÇAS (2)
acute myeloid leukemiaprecursor T-cell acute lymphoblastic leukemia
HGNC:15514UniProt:Q13492
RUNX1Runt-related transcription factor 1Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Forms the heterodimeric complex core-binding factor (CBF) with CBFB. RUNX members modulate the transcription of their target genes through recognizing the core consensus binding sequence 5'-TGTGGT-3', or very rarely, 5'-TGCGGT-3', within their regulatory regions via their runt domain, while CBFB is a non-DNA-binding regulatory subunit that allosterically enhances the sequence-specific DNA-binding capacity of RUNX. The heterodimers bind to the core site of a number of enhancers and promoters, inc

LOCALIZAÇÃO

Nucleus

VIAS BIOLÓGICAS (10)
Pre-NOTCH Transcription and TranslationRegulation of RUNX1 Expression and ActivityRUNX1 regulates genes involved in megakaryocyte differentiation and platelet functionRUNX3 regulates p14-ARFRUNX1 regulates transcription of genes involved in differentiation of keratinocytes
EXPRESSÃO TECIDUAL(Ubíquo)
Glândula salivar
31.0 TPM
Fibroblastos
22.0 TPM
Pulmão
18.9 TPM
Mama
18.8 TPM
Nervo tibial
13.1 TPM
OUTRAS DOENÇAS (6)
acute myeloid leukemiahereditary thrombocytopenia and hematologic cancer predisposition syndromehereditary thrombocytopenia and hematological cancer predisposition syndrome associated with RUNX1acute myeloid leukemia with t(8;21)(q22;q22) translocation
HGNC:10471UniProt:Q01196
SF3B1Splicing factor 3B subunit 1Disease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Component of the 17S U2 SnRNP complex of the spliceosome, a large ribonucleoprotein complex that removes introns from transcribed pre-mRNAs (PubMed:12234937, PubMed:27720643, PubMed:32494006, PubMed:34822310, PubMed:36104565). The 17S U2 SnRNP complex (1) directly participates in early spliceosome assembly and (2) mediates recognition of the intron branch site during pre-mRNA splicing by promoting the selection of the pre-mRNA branch-site adenosine, the nucleophile for the first step of splicing

LOCALIZAÇÃO

NucleusNucleus speckle

VIAS BIOLÓGICAS (5)
Dengue Virus-Host InteractionsmRNA Splicing - Major PathwaymRNA PolyadenylationmRNA Splicing - Minor PathwayB-WICH complex positively regulates rRNA expression
EXPRESSÃO TECIDUAL(Ubíquo)
Cervix Endocervix
245.2 TPM
Útero
235.8 TPM
Ovário
231.2 TPM
Cervix Ectocervix
226.6 TPM
Baço
211.5 TPM
OUTRAS DOENÇAS (3)
myelodysplastic syndromeuveal melanomamyelodysplastic syndrome with ring sideroblasts
HGNC:10768UniProt:O75533
GNB1Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1Disease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Guanine nucleotide-binding proteins (G proteins) are involved as a modulator or transducer in various transmembrane signaling systems (PubMed:29925951, PubMed:33762731, PubMed:34239069, PubMed:35610220, PubMed:35714614, PubMed:35835867, PubMed:36087581, PubMed:36989299, PubMed:37327704, PubMed:37935376, PubMed:37935377, PubMed:37963465, PubMed:37991948, PubMed:38168118, PubMed:38552625). The beta and gamma chains are required for the GTPase activity, for replacement of GDP by GTP, and for G prot

LOCALIZAÇÃO

VIAS BIOLÓGICAS (10)
Extra-nuclear estrogen signalingGPER1 signalingThromboxane signalling through TP receptorADORA2B mediated anti-inflammatory cytokines productionProstacyclin signalling through prostacyclin receptor
MECANISMO DE DOENÇA

Intellectual developmental disorder, autosomal dominant 42

A disorder characterized by significantly below average general intellectual functioning associated with impairments in adaptive behavior and manifested during the developmental period. MRD42 patients manifest global developmental delay commonly accompanied by hypotonia, seizures of various types, ophthalmological manifestations, and poor growth.

EXPRESSÃO TECIDUAL(Ubíquo)
Brain Frontal Cortex BA9
395.8 TPM
Cérebro - Hemisfério cerebelar
371.2 TPM
Fibroblastos
327.2 TPM
Córtex cerebral
325.9 TPM
Brain Anterior cingulate cortex BA24
308.4 TPM
OUTRAS DOENÇAS (3)
leukemia, acute lymphocytic, susceptibility to, 1myelodysplastic syndromeintellectual disability, autosomal dominant 42
HGNC:4396UniProt:P62873
CALRCalreticulinDisease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Calcium-binding chaperone that promotes folding, oligomeric assembly and quality control in the endoplasmic reticulum (ER) via the calreticulin/calnexin cycle. This lectin interacts transiently with almost all of the monoglucosylated glycoproteins that are synthesized in the ER (PubMed:7876246). Interacts with the DNA-binding domain of NR3C1 and mediates its nuclear export (PubMed:11149926). Involved in maternal gene expression regulation. May participate in oocyte maturation via the regulation

LOCALIZAÇÃO

Endoplasmic reticulum lumenCytoplasm, cytosolSecreted, extracellular space, extracellular matrixCell surfaceSarcoplasmic reticulum lumenCytoplasmic vesicle, secretory vesicle, Cortical granuleCytolytic granule

VIAS BIOLÓGICAS (2)
Antigen Presentation: Folding, assembly and peptide loading of class I MHCER-Phagosome pathway
OUTRAS DOENÇAS (4)
thrombocythemia 1primary myelofibrosisessential thrombocythemiaBudd-Chiari syndrome
HGNC:1455UniProt:P27797
SAMD9Sterile alpha motif domain-containing protein 9Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Double-stranded nucleic acid binding that acts as an antiviral factor by playing an essential role in the formation of cytoplasmic antiviral granules (PubMed:25428864, PubMed:28157624). May play a role in the inflammatory response to tissue injury and the control of extra-osseous calcification, acting as a downstream target of TNF signaling. Involved in the regulation of EGR1, in coordination with RGL2. May be involved in endosome fusion

LOCALIZAÇÃO

Cytoplasm

MECANISMO DE DOENÇA

Tumoral calcinosis, normophosphatemic, familial

An uncommon, life-threatening disorder characterized by progressive deposition of calcified masses in cutaneous and subcutaneous tissues. Serum phosphate levels are normal. Clinical features include painful calcified ulcerative lesions and massive calcium deposition in the mid- and lower dermis, severe skin and bone infections, erythematous papular skin eruption in infancy, conjunctivitis, and gingivitis. NFTC shows a striking resemblance to acquired dystrophic calcinosis, in which tissue calcification occurs as a consequence of tissue injury/inflammation.

EXPRESSÃO TECIDUAL(Ubíquo)
Esôfago - Mucosa
35.1 TPM
Linfócitos
20.1 TPM
Baço
16.0 TPM
Fibroblastos
11.7 TPM
Vagina
10.4 TPM
OUTRAS DOENÇAS (3)
MIRAGE syndromemonosomy 7 myelodysplasia and leukemia syndrome 2normophosphatemic familial tumoral calcinosis
HGNC:1348UniProt:Q5K651
SAMD9LSterile alpha motif domain-containing protein 9-likeDisease-causing germline mutation(s) inTolerante
FUNÇÃO

May be involved in endosome fusion. Mediates down-regulation of growth factor signaling via internalization of growth factor receptors

LOCALIZAÇÃO

Early endosomeMitochondrion

MECANISMO DE DOENÇA

Ataxia-pancytopenia syndrome

An autosomal dominant disorder characterized by cerebellar ataxia, variable hematologic cytopenias, and predisposition to bone marrow failure and myeloid leukemia.

EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
55.2 TPM
Baço
34.1 TPM
Pulmão
22.9 TPM
Nervo tibial
17.2 TPM
Cervix Endocervix
14.3 TPM
OUTRAS DOENÇAS (4)
monosomy 7 myelodysplasia and leukemia syndrome 1ataxia-pancytopenia syndromespinocerebellar ataxia 49SAMD9L-associated autoinflammatory syndrome
HGNC:1349UniProt:Q8IVG5
NF1NeurofibrominDisease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Stimulates the GTPase activity of Ras. NF1 shows greater affinity for Ras GAP, but lower specific activity. May be a regulator of Ras activity

LOCALIZAÇÃO

NucleusNucleus, nucleolusCell membrane

VIAS BIOLÓGICAS (1)
RAS signaling downstream of NF1 loss-of-function variants
MECANISMO DE DOENÇA

Neurofibromatosis 1

A disease characterized by patches of skin pigmentation (cafe-au-lait spots), Lisch nodules of the iris, tumors in the peripheral nervous system and fibromatous skin tumors. Individuals with the disorder have increased susceptibility to the development of benign and malignant tumors.

EXPRESSÃO TECIDUAL(Ubíquo)
Fibroblastos
17.9 TPM
Cérebro - Hemisfério cerebelar
17.1 TPM
Cerebelo
15.3 TPM
Nervo tibial
14.9 TPM
Tireoide
14.1 TPM
OUTRAS DOENÇAS (12)
neurofibromatosis, familial spinalneurofibromatosis type 1juvenile myelomonocytic leukemiaWatson syndrome
HGNC:7765UniProt:P21359
RARARetinoic acid receptor alphaDisease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Receptor for retinoic acid (PubMed:16417524, PubMed:19850744, PubMed:20215566, PubMed:21152046, PubMed:37478846). Retinoic acid receptors bind as heterodimers to their target response elements in response to their ligands, all-trans or 9-cis retinoic acid, and regulate gene expression in various biological processes (PubMed:21152046, PubMed:28167758, PubMed:37478846). The RXR/RAR heterodimers bind to the retinoic acid response elements (RARE) composed of tandem 5'-AGGTCA-3' sites known as DR1-DR

LOCALIZAÇÃO

NucleusCytoplasm

VIAS BIOLÓGICAS (5)
Activation of anterior HOX genes in hindbrain development during early embryogenesisNuclear Receptor transcription pathwayTranscriptional regulation of granulopoiesisTGFBR3 expressionSUMOylation of intracellular receptors
EXPRESSÃO TECIDUAL(Ubíquo)
Sangue
83.8 TPM
Pulmão
63.0 TPM
Cervix Endocervix
58.2 TPM
Fallopian Tube
57.2 TPM
Cervix Ectocervix
53.9 TPM
OUTRAS DOENÇAS (1)
acute promyelocytic leukemia
HGNC:9864UniProt:P10276
KITMast/stem cell growth factor receptor KitDisease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Tyrosine-protein kinase that acts as a cell-surface receptor for the cytokine KITLG/SCF and plays an essential role in the regulation of cell survival and proliferation, hematopoiesis, stem cell maintenance, gametogenesis, mast cell development, migration and function, and in melanogenesis. In response to KITLG/SCF binding, KIT can activate several signaling pathways. Phosphorylates PIK3R1, PLCG1, SH2B2/APS and CBL. Activates the AKT1 signaling pathway by phosphorylation of PIK3R1, the regulator

LOCALIZAÇÃO

Cell membraneCytoplasm

VIAS BIOLÓGICAS (5)
Developmental Lineage of Mammary Gland Luminal Epithelial CellsDevelopmental Lineage of Mammary Gland Alveolar CellsTFAP2 (AP-2) family regulates transcription of growth factors and their receptorsSignaling by SCF-KITRegulation of KIT signaling
MECANISMO DE DOENÇA

Piebald trait

Autosomal dominant genetic developmental abnormality of pigmentation characterized by congenital patches of white skin and hair that lack melanocytes.

EXPRESSÃO TECIDUAL(Ubíquo)
Esôfago - Muscular
44.5 TPM
Ovário
36.4 TPM
Esôfago - Junção
35.3 TPM
Cérebro - Hemisfério cerebelar
29.8 TPM
Tireoide
28.1 TPM
OUTRAS DOENÇAS (21)
gastrointestinal stromal tumorcutaneous mastocytosisacute myeloid leukemiapiebaldism
HGNC:6342UniProt:P10721
ABL1Tyrosine-protein kinase ABL1Disease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Non-receptor tyrosine-protein kinase that plays a role in many key processes linked to cell growth and survival such as cytoskeleton remodeling in response to extracellular stimuli, cell motility and adhesion, receptor endocytosis, autophagy, DNA damage response and apoptosis. Coordinates actin remodeling through tyrosine phosphorylation of proteins controlling cytoskeleton dynamics like WASF3 (involved in branch formation); ANXA1 (involved in membrane anchoring); DBN1, DBNL, CTTN, RAPH1 and ENA

LOCALIZAÇÃO

Cytoplasm, cytoskeletonNucleusMitochondrionNucleus membrane

VIAS BIOLÓGICAS (1)
Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks
MECANISMO DE DOENÇA

Leukemia, chronic myeloid

A clonal myeloproliferative disorder of a pluripotent stem cell with a specific cytogenetic abnormality, the Philadelphia chromosome (Ph), involving myeloid, erythroid, megakaryocytic, B-lymphoid, and sometimes T-lymphoid cells, but not marrow fibroblasts.

OUTRAS DOENÇAS (4)
chronic myelogenous leukemia, BCR-ABL1 positivecongenital heart defects and skeletal malformations syndromeB-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2)precursor T-cell acute lymphoblastic leukemia
HGNC:76UniProt:P00519
MPLThrombopoietin receptorDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Receptor for thrombopoietin that regulates hematopoietic stem cell renewal, megakaryocyte differentiation, and platelet formation. Upon activation by THPO, induces rapid tyrosine phosphorylation and activation of JAK2, providing docking sites for many signaling proteins such as STAT5, SHIP/INPP5D, GRB2, SOS1 and PI3K (PubMed:15899890, PubMed:37633268). In turn, These signaling cascades lead to the proliferation, survival, and differentiation of megakaryocytes, ultimately leading to increased pla

LOCALIZAÇÃO

Cell membraneGolgi apparatusCell surface

VIAS BIOLÓGICAS (1)
Platelet Aggregation (Plug Formation)
MECANISMO DE DOENÇA

Amegakaryocytic thrombocytopenia, congenital, 1

An autosomal recessive form of congenital amegakaryocytic thrombocytopenia, a hematologic disorder characterized by severe reduction of megakaryocytes and platelets at birth, and evolving into generalized bone marrow aplasia during childhood.

EXPRESSÃO TECIDUAL(Baixa expressão)
Testículo
1.5 TPM
Ovário
0.7 TPM
Pulmão
0.7 TPM
Nervo tibial
0.6 TPM
Tecido adiposo
0.5 TPM
OUTRAS DOENÇAS (6)
thrombocythemia 2primary myelofibrosiscongenital amegakaryocytic thrombocytopenia 1essential thrombocythemia
HGNC:7217UniProt:P40238
CEBPACCAAT/enhancer-binding protein alphaDisease-causing germline mutation(s) inModerado
FUNÇÃO

Transcription factor that coordinates proliferation arrest and the differentiation of myeloid progenitors, adipocytes, hepatocytes, and cells of the lung and the placenta. Binds directly to the consensus DNA sequence 5'-T[TG]NNGNAA[TG]-3' acting as an activator on distinct target genes (PubMed:11242107). During early embryogenesis, plays essential and redundant functions with CEBPB. Essential for the transition from common myeloid progenitors (CMP) to granulocyte/monocyte progenitors (GMP). Crit

LOCALIZAÇÃO

NucleusNucleus, nucleolus

VIAS BIOLÓGICAS (3)
Transcriptional regulation of granulopoiesisTranscriptional regulation of white adipocyte differentiationMLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis
MECANISMO DE DOENÇA

Leukemia, acute myelogenous

A subtype of acute leukemia, a cancer of the white blood cells. AML is a malignant disease of bone marrow characterized by maturational arrest of hematopoietic precursors at an early stage of development. Clonal expansion of myeloid blasts occurs in bone marrow, blood, and other tissue. Myelogenous leukemias develop from changes in cells that normally produce neutrophils, basophils, eosinophils and monocytes.

OUTRAS DOENÇAS (4)
acute myeloid leukemiainherited acute myeloid leukemiaacute myeloid leukemia with t(8;21)(q22;q22) translocationacute myeloid leukemia with CEBPA somatic mutations
HGNC:1833UniProt:P49715
JAK2Tyrosine-protein kinase JAK2Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Non-receptor tyrosine kinase involved in various processes such as cell growth, development, differentiation or histone modifications. Mediates essential signaling events in both innate and adaptive immunity. In the cytoplasm, plays a pivotal role in signal transduction via its association with type I receptors such as growth hormone (GHR), prolactin (PRLR), leptin (LEPR), erythropoietin (EPOR), thrombopoietin receptor (MPL/TPOR); or type II receptors including IFN-alpha, IFN-beta, IFN-gamma and

LOCALIZAÇÃO

Endomembrane systemCytoplasmNucleus

VIAS BIOLÓGICAS (10)
Interleukin-20 family signalingRAF activationSignaling downstream of RAS mutantsSignaling by moderate kinase activity BRAF mutantsParadoxical activation of RAF signaling by kinase inactive BRAF
EXPRESSÃO TECIDUAL(Ubíquo)
Artéria tibial
68.9 TPM
Aorta
46.9 TPM
Artéria coronária
31.6 TPM
Tecido adiposo
20.8 TPM
Nervo tibial
20.0 TPM
OUTRAS DOENÇAS (9)
thrombocythemia 3acquired polycythemia veraprimary myelofibrosisprimary familial polycythemia due to EPO receptor mutation
HGNC:6192UniProt:O60674
TET2Methylcytosine dioxygenase TET2Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Dioxygenase that catalyzes the conversion of the modified genomic base 5-methylcytosine (5mC) into 5-hydroxymethylcytosine (5hmC) and plays a key role in active DNA demethylation. Has a preference for 5-hydroxymethylcytosine in CpG motifs. Also mediates subsequent conversion of 5hmC into 5-formylcytosine (5fC), and conversion of 5fC to 5-carboxylcytosine (5caC). Conversion of 5mC into 5hmC, 5fC and 5caC probably constitutes the first step in cytosine demethylation. Methylation at the C5 position

LOCALIZAÇÃO

NucleusChromosome

VIAS BIOLÓGICAS (2)
TET1,2,3 and TDG demethylate DNASpecification of primordial germ cells
EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
12.3 TPM
Cervix Ectocervix
10.8 TPM
Vagina
10.4 TPM
Skin Not Sun Exposed Suprapubic
10.3 TPM
Skin Sun Exposed Lower leg
10.2 TPM
OUTRAS DOENÇAS (11)
myelodysplastic syndromeimmunodeficiency 75acute myeloid leukemia with multilineage dysplasiamyelodysplastic syndrome with ring sideroblasts
HGNC:25941UniProt:Q6N021
RPS14Small ribosomal subunit protein uS11Disease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Component of the small ribosomal subunit. The ribosome is a large ribonucleoprotein complex responsible for the synthesis of proteins in the cell. Part of the small subunit (SSU) processome, first precursor of the small eukaryotic ribosomal subunit. During the assembly of the SSU processome in the nucleolus, many ribosome biogenesis factors, an RNA chaperone and ribosomal proteins associate with the nascent pre-rRNA and work in concert to generate RNA folding, modifications, rearrangements and c

LOCALIZAÇÃO

CytoplasmNucleus, nucleolus

VIAS BIOLÓGICAS (10)
Formation of a pool of free 40S subunitsMajor pathway of rRNA processing in the nucleolus and cytosolSARS-CoV-2 modulates host translation machinerySARS-CoV-1 modulates host translation machineryViral mRNA Translation
EXPRESSÃO TECIDUAL(Ubíquo)
Ovário
1372.4 TPM
Linfócitos
1292.4 TPM
Skin Sun Exposed Lower leg
1008.0 TPM
Skin Not Sun Exposed Suprapubic
995.1 TPM
Cervix Ectocervix
953.5 TPM
OUTRAS DOENÇAS (1)
myelodysplastic syndrome associated with isolated del(5q)
HGNC:10387UniProt:P62263
GATA1Erythroid transcription factorDisease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Transcriptional activator or repressor which serves as a general switch factor for erythroid development (PubMed:35030251). It binds to DNA sites with the consensus sequence 5'-[AT]GATA[AG]-3' within regulatory regions of globin genes and of other genes expressed in erythroid cells. Activates the transcription of genes involved in erythroid differentiation of K562 erythroleukemia cells, including HBB, HBG1/2, ALAS2 and HMBS (PubMed:24245781)

LOCALIZAÇÃO

Nucleus

VIAS BIOLÓGICAS (3)
RUNX1 regulates genes involved in megakaryocyte differentiation and platelet functionRUNX1 regulates transcription of genes involved in differentiation of HSCsFactors involved in megakaryocyte development and platelet production
MECANISMO DE DOENÇA

X-linked dyserythropoietic anemia and thrombocytopenia

Disorder characterized by erythrocytes with abnormal size and shape, and paucity of platelets in peripheral blood. The bone marrow contains abundant and abnormally small megakaryocytes.

EXPRESSÃO TECIDUAL(Tecido-específico)
Sangue
25.8 TPM
Pulmão
3.7 TPM
Testículo
3.6 TPM
Baço
1.9 TPM
Pituitária
0.8 TPM
OUTRAS DOENÇAS (10)
transient myeloproliferative syndromethrombocytopenia, X-linked, with or without dyserythropoietic anemiahemolytic anemia due to erythrocyte adenosine deaminase overproductionX-linked dyserythropoetic anemia with abnormal platelets and neutropenia
HGNC:4170UniProt:P15976
PTPN11Tyrosine-protein phosphatase non-receptor type 11Disease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Acts downstream of various receptor and cytoplasmic protein tyrosine kinases to participate in the signal transduction from the cell surface to the nucleus (PubMed:10655584, PubMed:14739280, PubMed:18559669, PubMed:18829466, PubMed:26742426, PubMed:28074573, PubMed:32184441). Positively regulates MAPK signal transduction pathway (PubMed:28074573). Dephosphorylates GAB1, ARHGAP35 and EGFR (PubMed:28074573). Dephosphorylates ROCK2 at 'Tyr-722' resulting in stimulation of its RhoA binding activity

LOCALIZAÇÃO

CytoplasmNucleus

VIAS BIOLÓGICAS (10)
Activation of IRF3, IRF7 mediated by TBK1, IKKε (IKBKE)Spry regulation of FGF signalingRegulation of IFNA/IFNB signalingRegulation of IFNG signalingGPVI-mediated activation cascade
MECANISMO DE DOENÇA

LEOPARD syndrome 1

A disorder characterized by lentigines, electrocardiographic conduction abnormalities, ocular hypertelorism, pulmonic stenosis, abnormalities of genitalia, retardation of growth, and sensorineural deafness.

EXPRESSÃO TECIDUAL(Ubíquo)
Fibroblastos
111.4 TPM
Brain Spinal cord cervical c-1
108.7 TPM
Artéria tibial
90.4 TPM
Substância negra
83.1 TPM
Aorta
73.7 TPM
OUTRAS DOENÇAS (7)
juvenile myelomonocytic leukemiaNoonan syndrome 1metachondromatosisLEOPARD syndrome 1
HGNC:9644UniProt:Q06124
NUP214Nuclear pore complex protein Nup214Disease-causing germline mutation(s) inRestrito
FUNÇÃO

Part of the nuclear pore complex (PubMed:9049309). Has a critical role in nucleocytoplasmic transport (PubMed:31178128). May serve as a docking site in the receptor-mediated import of substrates across the nuclear pore complex (PubMed:31178128, PubMed:8108440) (Microbial infection) Required for capsid disassembly of the human adenovirus 5 (HadV-5) leading to release of the viral genome to the nucleus (in vitro)

LOCALIZAÇÃO

Nucleus, nuclear pore complex

VIAS BIOLÓGICAS (10)
snRNP AssemblyHCMV Early EventsHCMV Late EventsNEP/NS2 Interacts with the Cellular Export MachineryTransport of Ribonucleoproteins into the Host Nucleus
EXPRESSÃO TECIDUAL(Ubíquo)
Testículo
95.8 TPM
Baço
40.1 TPM
Linfócitos
26.7 TPM
Útero
25.7 TPM
Tireoide
25.3 TPM
OUTRAS DOENÇAS (5)
leukemia, acute lymphocytic, susceptibility to, 1acute myeloid leukemiaacute myeloid leukemia with t(6;9)(p23;q34)precursor T-cell acute lymphoblastic leukemia
HGNC:8064UniProt:P35658
NPM1NucleophosminDisease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Involved in diverse cellular processes such as ribosome biogenesis, centrosome duplication, protein chaperoning, histone assembly, cell proliferation, and regulation of tumor suppressors p53/TP53 and ARF. Binds ribosome presumably to drive ribosome nuclear export. Associated with nucleolar ribonucleoprotein structures and bind single-stranded nucleic acids. Acts as a chaperonin for the core histones H3, H2B and H4. Stimulates APEX1 endonuclease activity on apurinic/apyrimidinic (AP) double-stran

LOCALIZAÇÃO

Nucleus, nucleolusNucleus, nucleoplasmCytoplasm, cytoskeleton, microtubule organizing center, centrosome

VIAS BIOLÓGICAS (4)
PKR-mediated signalingTP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertainNuclear import of Rev proteinNuclear events stimulated by ALK signaling in cancer
EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
1517.5 TPM
Fibroblastos
1222.0 TPM
Ovário
1031.3 TPM
Cervix Endocervix
640.5 TPM
Útero
622.0 TPM
OUTRAS DOENÇAS (8)
acute myeloid leukemiaacute promyelocytic leukemiaacute myeloid leukemia with NPM1 somatic mutationsdyskeratosis congenita
HGNC:7910UniProt:P06748
KRASGTPase KRasDisease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Ras proteins bind GDP/GTP and possess intrinsic GTPase activity (PubMed:20949621, PubMed:39809765). Plays an important role in the regulation of cell proliferation (PubMed:22711838, PubMed:23698361). Activates MAPK1/MAPK3 resulting in phosphorylation and ultimately degradation of GJA1 (By similarity). Plays a role in promoting oncogenic events by inducing transcriptional silencing of tumor suppressor genes (TSGs) in colorectal cancer (CRC) cells in a ZNF304-dependent manner (PubMed:24623306)

LOCALIZAÇÃO

Cell membraneEndomembrane systemCytoplasm, cytosol

VIAS BIOLÓGICAS (2)
Signaling by moderate kinase activity BRAF mutantsRUNX3 regulates p14-ARF
MECANISMO DE DOENÇA

Leukemia, acute myelogenous

A subtype of acute leukemia, a cancer of the white blood cells. AML is a malignant disease of bone marrow characterized by maturational arrest of hematopoietic precursors at an early stage of development. Clonal expansion of myeloid blasts occurs in bone marrow, blood, and other tissue. Myelogenous leukemias develop from changes in cells that normally produce neutrophils, basophils, eosinophils and monocytes.

EXPRESSÃO TECIDUAL(Ubíquo)
Nervo tibial
30.7 TPM
Cérebro - Hemisfério cerebelar
25.1 TPM
Esôfago - Muscular
22.2 TPM
Esôfago - Mucosa
21.6 TPM
Esôfago - Junção
20.2 TPM
OUTRAS DOENÇAS (20)
gastric canceracute myeloid leukemialinear nevus sebaceous syndromeNoonan syndrome 3
HGNC:6407UniProt:P01116
ASXL1Polycomb group protein ASXL1Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Probable Polycomb group (PcG) protein involved in transcriptional regulation mediated by ligand-bound nuclear hormone receptors, such as retinoic acid receptors (RARs) and peroxisome proliferator-activated receptor gamma (PPARG) (PubMed:16606617). Acts as a coactivator of RARA and RXRA through association with NCOA1 (PubMed:16606617). Acts as a corepressor for PPARG and suppresses its adipocyte differentiation-inducing activity (By similarity). Non-catalytic component of the PR-DUB complex, a co

LOCALIZAÇÃO

Nucleus

VIAS BIOLÓGICAS (1)
UCH proteinases
MECANISMO DE DOENÇA

Bohring-Opitz syndrome

A syndrome characterized by severe intrauterine growth retardation, poor feeding, profound intellectual disability, trigonocephaly, prominent metopic suture, exophthalmos, nevus flammeus of the face, upslanting palpebral fissures, hirsutism, and flexion of the elbows and wrists with deviation of the wrists and metacarpophalangeal joints.

VIAS REACTOME (1)
OUTRAS DOENÇAS (6)
myelodysplastic syndromeBohring-Opitz syndromeaggressive systemic mastocytosisacute myeloid leukemia with multilineage dysplasia
HGNC:18318UniProt:Q8IXJ9
SH2B3SH2B adapter protein 3Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Links T-cell receptor activation signal to phospholipase C-gamma-1, GRB2 and phosphatidylinositol 3-kinase

LOCALIZAÇÃO

VIAS BIOLÓGICAS (3)
Regulation of KIT signalingNegative regulation of FLT3Factors involved in megakaryocyte development and platelet production
MECANISMO DE DOENÇA

Celiac disease 13

A multifactorial, chronic disorder of the small intestine caused by intolerance to gluten. It is characterized by immune-mediated enteropathy associated with failed intestinal absorption, and malnutrition. In predisposed individuals, the ingestion of gluten-containing food such as wheat and rye induces a flat jejunal mucosa with infiltration of lymphocytes.

EXPRESSÃO TECIDUAL(Ubíquo)
Baço
56.0 TPM
Linfócitos
43.0 TPM
Pulmão
41.6 TPM
Fibroblastos
37.9 TPM
Adipose Visceral Omentum
34.1 TPM
OUTRAS DOENÇAS (5)
primary myelofibrosisthrombocythemia 1primary familial polycythemia due to EPO receptor mutationgrowth retardation-mild developmental delay-chronic hepatitis syndrome
HGNC:29605UniProt:Q9UQQ2
ARHGAP26Rho GTPase-activating protein 26Disease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

GTPase-activating protein for RHOA and CDC42. Facilitates mitochondrial quality control by promoting Parkin-mediated recruitment of autophagosomes to damaged mitochondria (PubMed:38081847). Negatively regulates the growth of human parainfluenza virus type 2 by inhibiting hPIV-2-mediated RHOA activation via interaction with two of its viral proteins P and V (PubMed:27512058) Associates with MICAL1 on the endosomal membrane to promote Rab8-Rab10-dependent tubule extension. After dissociation of MI

LOCALIZAÇÃO

Endosome membraneCytoplasmCell junction, focal adhesionCytoplasm, cytoskeleton

VIAS BIOLÓGICAS (10)
RAC3 GTPase cycleRHOJ GTPase cycleRHOB GTPase cycleRAC1 GTPase cycleRHOD GTPase cycle
MECANISMO DE DOENÇA

Leukemia, juvenile myelomonocytic

An aggressive pediatric myelodysplastic syndrome/myeloproliferative disorder characterized by malignant transformation in the hematopoietic stem cell compartment with proliferation of differentiated progeny. Patients have splenomegaly, enlarged lymph nodes, rashes, and hemorrhages.

OUTRAS DOENÇAS (1)
juvenile myelomonocytic leukemia
HGNC:HGNC:17073UniProt:Q9UNA1
ETV6Transcription factor ETV6Disease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Transcriptional repressor; binds to the DNA sequence 5'-CCGGAAGT-3'. Plays a role in hematopoiesis and malignant transformation

LOCALIZAÇÃO

Nucleus

VIAS BIOLÓGICAS (1)
Signaling by FLT3 fusion proteins
EXPRESSÃO TECIDUAL(Ubíquo)
Artéria tibial
45.0 TPM
Glândula salivar
42.7 TPM
Skin Sun Exposed Lower leg
35.5 TPM
Linfócitos
30.0 TPM
Aorta
29.4 TPM
OUTRAS DOENÇAS (9)
acute myeloid leukemiathrombocytopenia 5B-lymphoblastic leukemia/lymphoma with t(12;21)(p13.2;q22.1)obsolete autosomal thrombocytopenia with normal platelets
HGNC:3495UniProt:P41212
FLT3Receptor-type tyrosine-protein kinase FLT3Disease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Tyrosine-protein kinase that acts as a cell-surface receptor for the cytokine FLT3LG and regulates differentiation, proliferation and survival of hematopoietic progenitor cells and of dendritic cells. Promotes phosphorylation of SHC1 and AKT1, and activation of the downstream effector MTOR. Promotes activation of RAS signaling and phosphorylation of downstream kinases, including MAPK1/ERK2 and/or MAPK3/ERK1. Promotes phosphorylation of FES, FER, PTPN6/SHP, PTPN11/SHP-2, PLCG1, and STAT5A and/or

LOCALIZAÇÃO

MembraneEndoplasmic reticulum lumen

VIAS BIOLÓGICAS (1)
FLT3 Signaling
MECANISMO DE DOENÇA

Leukemia, acute myelogenous

A subtype of acute leukemia, a cancer of the white blood cells. AML is a malignant disease of bone marrow characterized by maturational arrest of hematopoietic precursors at an early stage of development. Clonal expansion of myeloid blasts occurs in bone marrow, blood, and other tissue. Myelogenous leukemias develop from changes in cells that normally produce neutrophils, basophils, eosinophils and monocytes.

EXPRESSÃO TECIDUAL(Tecido-específico)
Cérebro - Hemisfério cerebelar
22.5 TPM
Cerebelo
19.7 TPM
Baço
5.4 TPM
Sangue
3.4 TPM
Brain Spinal cord cervical c-1
3.3 TPM
OUTRAS DOENÇAS (11)
leukemia, acute lymphocytic, susceptibility to, 1acute myeloid leukemiaB-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2)mixed phenotype acute leukemia with t(v;11q23.3)
HGNC:3765UniProt:P36888

Medicamentos e terapias

LENALIDOMIDEPhase 4

Mecanismo: CRL4(CRBN) E3 ubiquitin ligase modulator

DECITABINEPhase 4

Mecanismo: DNA (cytosine-5)-methyltransferase 3A inhibitor

AZACITIDINEPhase 4

Mecanismo: DNA (cytosine-5)-methyltransferase 3A inhibitor

LUSPATERCEPTPhase 4

Mecanismo: Transforming growth factor beta inhibitor

CEDAZURIDINEPhase 4

Mecanismo: Cytidine deaminase inhibitor

IDARUBICIN HYDROCHLORIDEPhase 4

Mecanismo: DNA topoisomerase II alpha inhibitor

GEMTUZUMAB OZOGAMICINPhase 4

Mecanismo: Myeloid cell surface antigen CD33 binding agent

SARGRAMOSTIMPhase 4

Mecanismo: Granulocyte-macrophage colony-stimulating factor receptor agonist

MIDOSTAURINPhase 4

Mecanismo: Protein kinase C (PKC) inhibitor

Ver mais no OpenTargets

Variantes genéticas (ClinVar)

263 variantes patogênicas registradas no ClinVar.

🧬 MLLT10: NM_001195626.3(MLLT10):c.2064-4A>G ()
🧬 MLLT10: NM_001195626.3(MLLT10):c.2064-18G>T ()
🧬 MLLT10: NM_001195626.3(MLLT10):c.1052-10T>A ()
🧬 MLLT10: NM_001195626.3(MLLT10):c.241-4A>G ()
🧬 MLLT10: GRCh37/hg19 10p14-q26.3(chr10:11138692-135427143) ()
Ver todas no ClinVar

Vias biológicas (Reactome)

429 vias biológicas associadas aos genes desta condição.

B-WICH complex positively regulates rRNA expression Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors Transcriptional regulation of granulopoiesis BMAL1:CLOCK,NPAS2 activates circadian expression PPARA activates gene expression NOTCH1 Intracellular Domain Regulates Transcription Transcriptional activation of mitochondrial biogenesis Activation of gene expression by SREBF (SREBP) Constitutive Signaling by NOTCH1 PEST Domain Mutants Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants HDACs deacetylate histones Notch-HLH transcription pathway Transcriptional regulation of white adipocyte differentiation Regulation of lipid metabolism by PPARalpha Loss of MECP2 binding ability to the NCoR/SMRT complex Regulation of MECP2 expression and activity NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux HCMV Early Events Cytoprotection by HMOX1 Heme signaling MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis Expression of BMAL (ARNTL), CLOCK, and NPAS2 RORA,B,C and NR1D1 (REV-ERBA) regulate gene expression RNA polymerase II transcribes snRNA genes SUMOylation of DNA damage response and repair proteins SUMOylation of ubiquitinylation proteins Regulation of TP53 Activity through Acetylation Interferon gamma signaling Regulation of RUNX1 Expression and Activity Regulation of PTEN localization Dengue virus activates/modulates innate and adaptive immune responses SUMOylation of transcription cofactors RHO GTPases Activate Formins Prolactin receptor signaling Interleukin-7 signaling Signaling by SCF-KIT Signaling by cytosolic FGFR1 fusion mutants Downstream signal transduction Signaling by Leptin Interleukin-3, Interleukin-5 and GM-CSF signaling Interleukin-20 family signaling Interleukin-15 signaling Interleukin-9 signaling Interleukin-2 signaling Interleukin-21 signaling Erythropoietin activates STAT5 STAT5 Activation Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants Signaling by CSF3 (G-CSF) STAT5 activation downstream of FLT3 ITD mutants Signaling by FLT3 fusion proteins Inactivation of CSF3 (G-CSF) signaling Growth hormone receptor signaling RUNX1 and FOXP3 control the development of regulatory T lymphocytes (Tregs) Transcriptional regulation by RUNX2 RUNX1 regulates estrogen receptor mediated transcription RUNX1 regulates expression of components of tight junctions RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function RUNX1 regulates transcription of genes involved in differentiation of HSCs RUNX1 regulates transcription of genes involved in differentiation of keratinocytes RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not known RUNX1 regulates transcription of genes involved in BCR signaling RUNX1 regulates transcription of genes involved in differentiation of myeloid cells RUNX1 regulates transcription of genes involved in interleukin signaling RUNX1 regulates transcription of genes involved in WNT signaling Regulation of RUNX2 expression and activity RUNX2 regulates osteoblast differentiation RUNX2 regulates chondrocyte maturation RUNX2 regulates bone development RUNX2 regulates genes involved in cell migration RUNX2 regulates genes involved in differentiation of myeloid cells Regulation of RUNX3 expression and activity RUNX3 Regulates Immune Response and Cell Migration RUNX3 regulates RUNX1-mediated transcription RUNX3 regulates p14-ARF Estrogen-dependent gene expression EPHA-mediated growth cone collapse Sema4D induced cell migration and growth-cone collapse Smooth Muscle Contraction RHO GTPases activate PKNs RHO GTPases activate CIT RHO GTPases Activate ROCKs RHO GTPases activate PAKs Developmental Lineage of Mammary Gland Myoepithelial Cells PKMTs methylate histone lysines Formation of WDR5-containing histone-modifying complexes Regulation of PD-L1(CD274) transcription Phosphorylated BMAL1:CLOCK (ARNTL:CLOCK) activates expression of core clock genes Phosphorylation of CLOCK, acetylation of BMAL1 (ARNTL) at target gene promoters The CRY:PER:kinase complex represses transactivation by the BMAL:CLOCK (ARNTL:CLOCK) complex HATs acetylate histones Regulation of gene expression by Hypoxia-inducible Factor Pre-NOTCH Transcription and Translation Formation of the beta-catenin:TCF transactivating complex Regulation of gene expression in late stage (branching morphogenesis) pancreatic bud precursor cells LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production Attenuation phase Activation of anterior HOX genes in hindbrain development during early embryogenesis CD209 (DC-SIGN) signaling TP53 Regulates Transcription of Genes Involved in Cytochrome C Release Activation of the TFAP2 (AP-2) family of transcription factors RUNX3 regulates NOTCH signaling NOTCH3 Intracellular Domain Regulates Transcription NOTCH4 Intracellular Domain Regulates Transcription TRAF3-dependent IRF activation pathway TRAF6 mediated IRF7 activation FOXO-mediated transcription of cell death genes Neddylation Antigen processing: Ubiquitination & Proteasome degradation Recruitment of NuMA to mitotic centrosomes Mitotic Prophase Transport of Mature mRNA Derived from an Intronless Transcript mRNA 3'-end processing RNA Polymerase II Transcription Termination Processing of Intronless Pre-mRNAs Signaling by cytosolic PDGFRA and PDGFRB fusion proteins mRNA Polyadenylation Dengue Virus-Host Interactions Interleukin-6 signaling BH3-only proteins associate with and inactivate anti-apoptotic BCL-2 members Signalling to STAT3 Signaling by ALK Senescence-Associated Secretory Phenotype (SASP) POU5F1 (OCT4), SOX2, NANOG activate genes related to proliferation Association of TriC/CCT with target proteins during biosynthesis Transcriptional regulation of pluripotent stem cells Interleukin-10 signaling Interleukin-4 and Interleukin-13 signaling PTK6 Activates STAT3 MET activates STAT3 Interleukin-35 Signalling Interleukin-37 signaling Interleukin-23 signaling Interleukin-27 signaling Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants Signaling by PDGFRA extracellular domain mutants PIP3 activates AKT signaling Signaling by PDGF Constitutive Signaling by Aberrant PI3K in Cancer RAF/MAP kinase cascade PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling Activation of NOXA and translocation to mitochondria Activation of PUMA and translocation to mitochondria Oxidative Stress Induced Senescence Formation of Senescence-Associated Heterochromatin Foci (SAHF) Oncogene Induced Senescence DNA Damage/Telomere Stress Induced Senescence SUMOylation of transcription factors Autodegradation of the E3 ubiquitin ligase COP1 Pyroptosis TP53 Regulates Metabolic Genes Ub-specific processing proteases Ovarian tumor domain proteases Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks TP53 Regulates Transcription of DNA Repair Genes TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertain TP53 Regulates Transcription of Caspase Activators and Caspases TP53 Regulates Transcription of Death Receptors and Ligands TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest Regulation of TP53 Expression Regulation of TP53 Activity through Phosphorylation Regulation of TP53 Degradation Regulation of TP53 Activity through Association with Co-factors Regulation of TP53 Activity through Methylation PKA activation PKA activation in glucagon signalling DARPP-32 events Glucagon-like Peptide-1 (GLP1) regulates insulin secretion Vasopressin regulates renal water homeostasis via Aquaporins CREB1 phosphorylation through the activation of Adenylate Cyclase Hedgehog 'off' state GPER1 signaling ADORA2B mediated anti-inflammatory cytokines production FCGR3A-mediated IL10 synthesis ALK mutants bind TKIs Signaling by ALK fusions and activated point mutants Factors involved in megakaryocyte development and platelet production High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells Signaling by FGFR1 in disease RHOA GTPase cycle RHOB GTPase cycle RHOC GTPase cycle CDC42 GTPase cycle RAC1 GTPase cycle RAC2 GTPase cycle RAC3 GTPase cycle LPPR2 LPPR5 LPPR4(LPPR1-3,5) Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants Spry regulation of FGF signaling Regulation of KIT signaling EGFR downregulation TGF-beta receptor signaling activates SMADs Constitutive Signaling by EGFRvIII Negative regulation of FGFR1 signaling Negative regulation of FGFR2 signaling Negative regulation of FGFR3 signaling Negative regulation of FGFR4 signaling Negative regulation of MET activity PTK6 Regulates RTKs and Their Effectors AKT1 and DOK1 Cargo recognition for clathrin-mediated endocytosis Clathrin-mediated endocytosis InlB-mediated entry of Listeria monocytogenes into host cell Regulation of signaling by CBL Signaling by CSF1 (M-CSF) in myeloid cells Negative regulation of FLT3 FLT3 signaling by CBL mutants Signaling by ERBB2 Nuclear signaling by ERBB4 Downregulation of ERBB4 signaling p38MAPK events Signaling by EGFR GAB1 signalosome Regulation of gap junction activity FCGR activation PECAM1 interactions EPH-Ephrin signaling Integrin signaling GRB2:SOS provides linkage to MAPK signaling for Integrins p130Cas linkage to MAPK signaling for integrins NCAM signaling for neurite out-growth Co-stimulation by CD28 Co-inhibition by CTLA4 Signal regulatory protein family interactions EPHB-mediated forward signaling Ephrin signaling EPH-ephrin mediated repulsion of cells G alpha (s) signalling events ADP signalling through P2Y purinoceptor 1 PRC2 methylates histones and DNA RMTs methylate histone arginines SUMOylation of DNA methylation proteins DNA methylation Defective pyroptosis Regulation of endogenous retroelements by Piwi-interacting RNAs (piRNAs) Golgi Associated Vesicle Biogenesis RND3 GTPase cycle SLC-mediated transport of organic cations SARS-CoV-1 activates/modulates innate immune responses Differentiation of naive CD+ T cells to T helper 1 cells (Th1 cells) mRNA Splicing - Major Pathway mRNA Splicing - Minor Pathway Activation of G protein gated Potassium channels Glucagon signaling in metabolic regulation G-protein activation Activation of the phototransduction cascade Inactivation, recovery and regulation of the phototransduction cascade Olfactory Signaling Pathway Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1) ADP signalling through P2Y purinoceptor 12 G beta:gamma signalling through PI3Kgamma Prostacyclin signalling through prostacyclin receptor Adrenaline,noradrenaline inhibits insulin secretion Ca2+ pathway G alpha (q) signalling events G alpha (12/13) signalling events G beta:gamma signalling through PLC beta G alpha (i) signalling events G alpha (z) signalling events Glucagon-type ligand receptors Thromboxane signalling through TP receptor Thrombin signalling through proteinase activated receptors (PARs) Presynaptic function of Kainate receptors Cooperation of PDCL (PhLP1) and TRiC/CCT in G-protein beta folding G beta:gamma signalling through BTK G beta:gamma signalling through CDC42 Extra-nuclear estrogen signaling ER-Phagosome pathway Assembly of Viral Components at the Budding Site Scavenging by Class A Receptors Scavenging by Class F Receptors ATF6 (ATF6-alpha) activates chaperone genes Calnexin/calreticulin cycle Antigen Presentation: Folding, assembly and peptide loading of class I MHC Maturation of DENV proteins Regulation of RAS by GAPs RAS signaling downstream of NF1 loss-of-function variants Nuclear Receptor transcription pathway SUMOylation of intracellular receptors Signaling by Retinoic Acid TGFBR3 expression TFAP2 (AP-2) family regulates transcription of growth factors and their receptors Dasatinib-resistant KIT mutants Imatinib-resistant KIT mutants KIT mutants bind TKIs Masitinib-resistant KIT mutants Nilotinib-resistant KIT mutants Regorafenib-resistant KIT mutants Signaling by kinase domain mutants of KIT Sunitinib-resistant KIT mutants Signaling by juxtamembrane domain KIT mutants Sorafenib-resistant KIT mutants Signaling by extracellular domain mutants of KIT Transcriptional and post-translational regulation of MITF-M expression and activity Developmental Lineage of Mammary Gland Luminal Epithelial Cells Developmental Lineage of Mammary Gland Alveolar Cells Regulation of actin dynamics for phagocytic cup formation Role of ABL in ROBO-SLIT signaling Myogenesis RHO GTPases Activate WASPs and WAVEs HDR through Single Strand Annealing (SSA) Cyclin D associated events in G1 FCGR3A-mediated phagocytosis Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells Platelet Aggregation (Plug Formation) MAPK3 (ERK1) activation MAPK1 (ERK2) activation RAF activation IL-6-type cytokine receptor ligand interactions Signaling by moderate kinase activity BRAF mutants Signaling by BRAF and RAF1 fusions Paradoxical activation of RAF signaling by kinase inactive BRAF Regulation of IFNG signaling Signaling by Erythropoietin Interleukin-12 signaling Erythropoietin activates Phosphoinositide-3-kinase (PI3K) Erythropoietin activates Phospholipase C gamma (PLCG) Erythropoietin activates RAS Interleukin receptor SHC signaling Signaling downstream of RAS mutants TET1,2,3 and TDG demethylate DNA Specification of primordial germ cells L13a-mediated translational silencing of Ceruloplasmin expression Peptide chain elongation SRP-dependent cotranslational protein targeting to membrane Viral mRNA Translation Selenocysteine synthesis rRNA modification in the nucleus and cytosol Major pathway of rRNA processing in the nucleolus and cytosol Translation initiation complex formation Formation of a pool of free 40S subunits Formation of the ternary complex, and subsequently, the 43S complex Ribosomal scanning and start codon recognition GTP hydrolysis and joining of the 60S ribosomal subunit Eukaryotic Translation Termination Regulation of expression of SLITs and ROBOs Response of EIF2AK4 (GCN2) to amino acid deficiency SARS-CoV-1 modulates host translation machinery SARS-CoV-2 modulates host translation machinery Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC) Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC) PELO:HBS1L and ABCE1 dissociate a ribosome on a non-stop mRNA ZNF598 and the Ribosome-associated Quality Trigger (RQT) complex dissociate a ribosome stalled on a no-go mRNA PI3K Cascade GPVI-mediated activation cascade Tie2 Signaling Co-inhibition by PD-1 Netrin mediated repulsion signals Platelet sensitization by LDL PI-3K cascade:FGFR1 FRS-mediated FGFR1 signaling PI-3K cascade:FGFR2 FRS-mediated FGFR2 signaling FRS-mediated FGFR3 signaling PI-3K cascade:FGFR3 FRS-mediated FGFR4 signaling PI-3K cascade:FGFR4 ISG15 antiviral mechanism Transport of the SLBP independent Mature mRNA Transport of the SLBP Dependant Mature mRNA Transport of Mature mRNA derived from an Intron-Containing Transcript Rev-mediated nuclear export of HIV RNA Transport of Ribonucleoproteins into the Host Nucleus NS1 Mediated Effects on Host Pathways Viral Messenger RNA Synthesis NEP/NS2 Interacts with the Cellular Export Machinery Regulation of Glucokinase by Glucokinase Regulatory Protein Nuclear import of Rev protein Vpr-mediated nuclear import of PICs snRNP Assembly Nuclear Pore Complex (NPC) Disassembly Regulation of HSF1-mediated heat shock response SUMOylation of SUMOylation proteins HuR (ELAVL1) binds and stabilizes mRNA SUMOylation of chromatin organization proteins SUMOylation of RNA binding proteins SUMOylation of DNA replication proteins Defective TPR may confer susceptibility towards thyroid papillary carcinoma (TPC) tRNA processing in the nucleus HCMV Late Events SARS-CoV-2 activates/modulates innate and adaptive immune responses Deposition of new CENPA-containing nucleosomes at the centromere TFAP2A acts as a transcriptional repressor during retinoic acid induced cell differentiation SARS-CoV-1-host interactions Nuclear events stimulated by ALK signaling in cancer PKR-mediated signaling SOS-mediated signalling Activation of RAS in B cells SHC1 events in ERBB2 signaling SHC1 events in ERBB4 signaling Signalling to RAS GRB2 events in EGFR signaling SHC1 events in EGFR signaling GRB2 events in ERBB2 signaling EGFR Transactivation by Gastrin DAP12 signaling SHC-related events triggered by IGF1R FCERI mediated MAPK activation Ras activation upon Ca2+ influx through NMDA receptor VEGFR2 mediated cell proliferation SHC-mediated cascade:FGFR1 SHC-mediated cascade:FGFR2 SHC-mediated cascade:FGFR3 UCH proteinases RHOD GTPase cycle RHOQ GTPase cycle RHOJ GTPase cycle Signaling by membrane-tethered fusions of PDGFRA or PDGFRB FLT3 Signaling FLT3 mutants bind TKIs KW2449-resistant FLT3 mutants semaxanib-resistant FLT3 mutants crenolanib-resistant FLT3 mutants gilteritinib-resistant FLT3 mutants lestaurtinib-resistant FLT3 mutants midostaurin-resistant FLT3 mutants pexidartinib-resistant FLT3 mutants ponatinib-resistant FLT3 mutants quizartinib-resistant FLT3 mutants sorafenib-resistant FLT3 mutants sunitinib-resistant FLT3 mutants tandutinib-resistant FLT3 mutants linifanib-resistant FLT3 mutants tamatinib-resistant FLT3 mutants Signaling by FLT3 ITD and TKD mutants FLT3 signaling through SRC family kinases

Diagnóstico

Os sinais que médicos procuram e os exames que confirmam

Carregando...

Tratamento e manejo

Remédios, cuidados de apoio e o que precisa acompanhar

Pipeline de tratamentos
Pipeline regulatório — de medicamentos já aprovados a drogas em pesquisa exploratória.
Aprovado9
Medicamentos catalogadosEnsaios clínicos· 9 medicamentos · 0 ensaios
✓ Aprovados — podem ser usados hoje
LENALIDOMIDEDECITABINEAZACITIDINELUSPATERCEPTCEDAZURIDINEIDARUBICIN HYDROCHLORIDEGEMTUZUMAB OZOGAMICINSARGRAMOSTIMMIDOSTAURIN
Carregando informações de tratamento...

Onde tratar no SUS

Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)

🇧🇷 Atendimento SUS — Hemopatia mieloide

🗺️

Selecione um estado ou use sua localização para ver resultados.

Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.

Pesquisa ativa

Ensaios clínicos abertos e novidades científicas recentes

Pesquisa e ensaios clínicos

Nenhum ensaio clínico registrado para esta condição.

🧪 Está conduzindo uma pesquisa?
Divulgue para pacientes e familiares que acompanham esta doença.
Divulgar pesquisa →

Publicações mais relevantes

Timeline de publicações
0 papers (10 anos)
#1

[Recommendations from the GBMHM and the Fi-LMC for the diagnosis and management of chronic myeloid leukemia].

Bulletin du cancer2026 Apr

Para pacientes e médicos, biólogos moleculares são cruciais na Leucemia Mieloide Crônica (LMC). Eles identificam a fusão BCR::ABL1 para o diagnóstico e monitoram a doença residual (DRM) durante o tratamento, avaliando a resposta e identificando resistência. Essas análises guiam a adaptação do tratamento, especialmente em casos de resistência (identificando mutações), garantindo decisões terapêuticas otimizadas e o melhor cuidado ao paciente.

🇧🇷 traduzido
#2

Midostaurin shapes macroclonal and microclonal evolution of FLT3-mutated acute myeloid leukemia.

Blood advances2025 Jan 28

Este estudo sobre leucemia mieloide aguda (LMA) com mutação FLT3-ITD e o uso de midostaurina (MIDO) revelou que, embora a MIDO reduza a persistência da mutação na recidiva, a presença de múltiplos clones FLT3-ITD no diagnóstico está associada a maior persistência da doença mesmo com o tratamento. Além disso, microclones podem evoluir para se tornarem dominantes na recidiva. Para pacientes e médicos, isso indica que a avaliação da diversidade clonal no diagnóstico é crucial para entender o risco de recaída e planejar estratégias terapêuticas mais eficazes.

🇧🇷 traduzido
#3

Analysis of peripheral neuropathy in the POLARIX study using clinician- and patient-reported outcomes.

Blood advances2025 Jul 08
#4

Conditional survival of children, adolescents and young adults (0-24 years) diagnosed with leukaemia during 2000-2014 world-wide: (CONCORD-3).

European journal of cancer (Oxford, England : 1990)2025 Jul 25

Este estudo global sobre a leucemia em crianças, adolescentes e jovens adultos (0-24 anos) destaca que a sobrevida condicional – a probabilidade de viver mais tempo após ter sobrevivido aos primeiros anos – é um indicador crucial. Para pacientes com leucemia mieloide aguda, a sobrevida é consistentemente 5-10% menor do que para a leucemia linfoide, e embora crianças em países de alta renda apresentem taxas de sobrevida acima de 90%, pacientes mais velhos e de países de baixa renda enfrentam prognósticos menos favoráveis. Contudo, superar os primeiros anos após o diagnóstico melhora significativamente as chances de sobrevida a longo prazo, enfatizando a importância do acesso precoce e contínuo a tratamentos ótimos para médicos e pacientes.

🇧🇷 traduzido
#5

Survival of European children, adolescents and young adults diagnosed with haematological malignancies in the period 2000-2013: Results from EUROCARE-6, a population-based study.

European journal of cancer (Oxford, England : 1990)2025 Jun 03

Este estudo europeu sobre hemopatias mieloides revela que adolescentes e jovens adultos (AYAs) geralmente apresentam uma sobrevida pior para leucemia mieloide aguda (LMA) em comparação com crianças, embora tenham melhor prognóstico para leucemia mieloide crônica (LMC). Apesar do aumento da sobrevida para AYAs com LMA e LMC entre 2000 e 2013, o estudo sublinha que, para a maioria das hemopatias, o prognóstico dos AYAs ainda é inferior ao das crianças. Para médicos e pacientes, isso enfatiza a necessidade contínua de mais pesquisas e terapias especializadas para melhorar a sobrevida deste grupo etário.

🇧🇷 traduzido

Publicações recentes

Ver todas no PubMed

📚 EuropePMCmostrando 77

2026

[Recommendations from the GBMHM and the Fi-LMC for the diagnosis and management of chronic myeloid leukemia].

Bulletin du cancer
2025

Conditional survival of children, adolescents and young adults (0-24 years) diagnosed with leukaemia during 2000-2014 world-wide: (CONCORD-3).

European journal of cancer (Oxford, England : 1990)
2025

Survival of European children, adolescents and young adults diagnosed with haematological malignancies in the period 2000-2013: Results from EUROCARE-6, a population-based study.

European journal of cancer (Oxford, England : 1990)
2025

Short-term neurological tolerance of chimeric antigen receptor-T cell therapy for refractory B-cell malignancy in patients with pre-existing cognitive impairment: A retrospective cohort study.

Journal of geriatric oncology
2025

Analysis of peripheral neuropathy in the POLARIX study using clinician- and patient-reported outcomes.

Blood advances
2025

Long-term survival for myeloid neoplasms and national health expenditure: A EUROCARE-6 retrospective, population-based study.

European journal of cancer (Oxford, England : 1990)
2025

HLA evolutionary divergence score after donor lymphocyte infusion following allogeneic hematopoietic stem cell transplantation.

HemaSphere
2025

[VEXAS-like auto inflammatory syndrome: 2 cases].

La Revue de medecine interne
2024

Macrophages as Potential Therapeutic Targets in Acute Myeloid Leukemia.

Biomedicines
2025

Midostaurin shapes macroclonal and microclonal evolution of FLT3-mutated acute myeloid leukemia.

Blood advances
2025

[Place of hematopoietic stem cell transplantation for very high risk acute myeloblastic leukemia and myelodysplastic syndromes (SFGM-TC)].

Bulletin du cancer
2025

Sodium diethyldithiocarbamate trihydrate: an effective and selective compound for hematological malignancies.

Naunyn-Schmiedeberg's archives of pharmacology
2024

From Skin to Blood: Ulcerative Pyoderma Gangrenosum Unveiling Acute Myeloid Leukemia.

Cureus
2024

Optimized cytogenetic risk-group stratification of KMT2A-rearranged pediatric acute myeloid leukemia.

Blood advances
2024

The t(X;20)(q13;q13) translocation is a good prognostic factor in myeloid neoplasms: A report of 25 cases from the Groupe Francophone de Cytogénétique Hématologique.

American journal of hematology
2024

Leukemia cutis revealing relapse of a chronic myeloid leukemia: A case report.

Clinical case reports
2024

Integrative single-cell expression and functional studies unravels a sensitization to cytarabine-based chemotherapy through HIF pathway inhibition in AML leukemia stem cells.

HemaSphere
2024

Single-cell Multiomics Analysis of Myelodysplastic Syndromes and Clinical Response to Hypomethylating Therapy.

Cancer research communications
2023

Cytogenetics in the management of acute myeloid leukemia and histiocytic/dendritic cell neoplasms: Guidelines from the Groupe Francophone de Cytogénétique Hématologique (GFCH).

Current research in translational medicine
2023

A human genome editing-based MLL::AF4 ALL model recapitulates key cellular and molecular leukemogenic features.

Blood
2023

[Dysimmune manifestations associated with myelodysplastic neoplasms and chronic myelomonocytic leukaemias].

Bulletin du cancer
2023

Measurable Residual Disease and Fusion Partner Independently Predict Survival and Relapse Risk in Childhood KMT2A-Rearranged Acute Myeloid Leukemia: A Study by the International Berlin-Frankfurt-Münster Study Group.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2023

A miRNA signature related to stemness identifies high-risk patients in paediatric acute myeloid leukaemia.

British journal of haematology
2023

Hereditary predisposition to malignant myeloid hemopathies: Caution in use of saliva and guideline based on our experience.

Frontiers in oncology
2023

Factors influencing access to specialised haematology units during acute myeloblastic leukaemia patient care: A population-based study in France.

Cancer medicine
2023

TIM3, a human acute myeloid leukemia stem cell marker, does not enrich for leukemia-initiating stem cells in B-cell acute lymphoblastic leukemia.

Haematologica
2023

The presence of a chromosomal abnormality in cytopenia without dysplasia identifies a category of high-risk clonal cytopenia of unknown significance.

Genes, chromosomes & cancer
2023

Hypodiploidy has unfavorable impact on survival in pediatric acute myeloid leukemia: an I-BFM Study Group collaboration.

Blood advances
2022

Critical Role of Aquaporins in Cancer: Focus on Hematological Malignancies.

Cancers
2022

Genetics and Epigenetics in Neoplasms with Plasmacytoid Dendritic Cells.

Cancers
2023

Reduced peripheral blood dendritic cell and monocyte subsets in MDS patients with systemic inflammatory or dysimmune diseases.

Clinical and experimental medicine
2022

Venous thromboembolism during systemic inflammatory and autoimmune diseases associated with myelodysplastic syndromes, chronic myelomonocytic leukaemia and myelodysplastic/myeloproliferative neoplasms: a French multicentre retrospective case-control study.

Clinical and experimental rheumatology
2022

[Prevalence of Adverse Effects of Tyrosine Kinase Inhibitors Used in Management of Chronic Myeloid Leukemia at Sidi Bel-Abbès University Hospital Center].

Annales pharmaceutiques francaises
2022

Photodistributed pustular acute febrile neutrophilic dermatosis revealing an acute myeloid leukemia.

Clinical case reports
2022

Hidden in the Eyes-Recurrence of Systemic Hemopathies Reportedly "In Remission": Six Cases and Review of Literature.

Medicina (Kaunas, Lithuania)
2022

Nodal cytotoxic peripheral T-cell lymphoma occurs frequently in the clinical setting of immunodysregulation and is associated with recurrent epigenetic alterations.

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
2022

Donor-Derived Leukemia in a Recipient of Double-Unit Cord Blood Transplantation for Acute Myeloid Leukemia: A Case Study and Literature Review.

Oncology and therapy
2021

Novel agents for myelodysplastic syndromes.

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
2021

Second- or third-generation tyrosine kinase inhibitors in first-line treatment of chronic myeloid leukemia in general population: Is there a real benefit?

Cancer medicine
2021

Myeloid malignancies with translocation t(4;12)(q11-13;p13): molecular landscape, clonal hierarchy and clinical outcomes.

Journal of cellular and molecular medicine
2021

Multiple cranial nerve palsies revealing blast crisis in patient with chronic myeloid leukemia in the accelerated phase under nilotinib during severe infection with SARS-COV-19 virus: Case report and review of literature.

Radiology case reports
2021

Epigenetic focus on angioimmunoblastic T-cell lymphoma: pathogenesis and treatment.

Current opinion in oncology
2021

[Overview of the general management of acute leukemia for adults].

Revue medicale de Liege
2021

An overview of genetic predisposition to familial hematological malignancies.

Bulletin du cancer
2021

Flexible Modeling of Net Survival and Cure by AML Subtype and Age: A French Population-Based Study from FRANCIM.

Journal of clinical medicine
2021

Heamatological malignancies in giant cell arteritis: a French population-based study.

Rheumatology (Oxford, England)
2021

[Behçet's-like syndrome and other dysimmunitary manifestations related to myelodysplastic syndromes with trisomy 8].

La Revue de medecine interne
2020

[Erythrophagocytosis by blast cells and de novo T cell LAL without cytogenetic abnormalities in a Moroccan patient].

The Pan African medical journal
2020

Clonal haematopoiesis is increased in early onset in systemic sclerosis.

Rheumatology (Oxford, England)
2020

Long-term overall survival and toxicities of ABVD vs BEACOPP in advanced Hodgkin lymphoma: A pooled analysis of four randomized trials.

Cancer medicine
2020

[Diagnostic workup in front of an hypereosinophilia in 2020].

Annales de biologie clinique
2020

Infant cancers in France: Incidence and survival (2000-2014).

Cancer epidemiology
2020

Correlation of histological marrow characteristics and intravoxel incoherent motion-derived parameters in benign and malignant hematological disorders.

European journal of radiology
2020

[Haploidentical hematopoietic stem cell transplant: How to choose the best donor? Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)].

Bulletin du cancer
2020

[Recommendations from the French CML Study Group (Fi-LMC) for BCR-ABL1 kinase domain mutation analysis in chronic myeloid leukemia].

Bulletin du cancer
2019

[Clonal haematopoiesis: A concise review].

La Revue de medecine interne
2019

Using healthcare claims data to analyze the prevalence of BCR-ABL-positive chronic myeloid leukemia in France: A nationwide population-based study.

Cancer medicine
2019

A novel thiosemicarbazone as a promising effective and selective compound for acute leukemia.

Anti-cancer drugs
2019

PREDOMOS study, impact of a social intervention program for socially isolated elderly cancer patients: update to the study protocol for a randomized controlled trial.

Trials
2019

Poor prognosis of chromosome 7 clonal aberrations in Philadelphia-negative metaphases and relevance of potential underlying myelodysplastic features in chronic myeloid leukemia.

Haematologica
2019

MICONIDINE acetate, a new selective and cytotoxic compound with synergic potential, induces cell cycle arrest and apoptosis in leukemia cells.

Investigational new drugs
2018

Stable Isotope Labeling Highlights Enhanced Fatty Acid and Lipid Metabolism in Human Acute Myeloid Leukemia.

International journal of molecular sciences
2019

Inflammatory disorders associated with trisomy 8-myelodysplastic syndromes: French retrospective case-control study.

European journal of haematology
2018

Epidemiology of malignant hemopathies recorded in hospitals in Cameroon.

Medecine et sante tropicales
2018

To chelate or not to chelate in MDS: That is the question!

Blood reviews
2018

Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries.

Lancet (London, England)
2017

In Vitro Culture with Interleukin-15 Leads to Expression of Activating Receptors and Recovery of Natural Killer Cell Function in Acute Myeloid Leukemia Patients.

Frontiers in immunology
2016

The IDH2 R172K mutation associated with angioimmunoblastic T-cell lymphoma produces 2HG in T cells and impacts lymphoid development.

Proceedings of the National Academy of Sciences of the United States of America
2017

Biological and Clinical Relevance of Associated Genomic Alterations in MYD88 L265P and non-L265P-Mutated Diffuse Large B-Cell Lymphoma: Analysis of 361 Cases.

Clinical cancer research : an official journal of the American Association for Cancer Research
2016

Cytogenetics in the management of acute myeloid leukemia: an update by the Groupe francophone de cytogénétique hématologique (GFCH).

Annales de biologie clinique
2016

Cancer incidence in France over the 1980-2012 period: Hematological malignancies.

Revue d'epidemiologie et de sante publique
2016

The level of blast CD33 expression positively impacts the effect of gemtuzumab ozogamicin in patients with acute myeloid leukemia.

Blood
2015

A minireview on NHE1 inhibitors. A rediscovered hope in oncohematology.

Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia
2015

[Myelodysplastic syndromes: pathophysiology, clinical and biological features].

Annales de biologie clinique
2015

Survival variations by country and age for lymphoid and myeloid malignancies in Europe 2000-2007: Results of EUROCARE-5 population-based study.

European journal of cancer (Oxford, England : 1990)
2015

Molecular characterization and follow-up of five CML patients with new BCR-ABL1 fusion transcripts.

Genes, chromosomes & cancer
2015

3q26/EVI1 rearrangements in myeloid hemopathies: a cytogenetic review.

Future oncology (London, England)

Associações

Organizações que acompanham esta doença — pra ter apoio e orientação

Ainda não temos associações cadastradas para Hemopatia mieloide.

É de uma associação que acompanha esta doença? Fale com a gente →

Comunidades

Grupos ativos de quem convive com esta doença aqui no Raras

Ainda não existe comunidade no Raras para Hemopatia mieloide

Pacientes, familiares e cuidadores se organizam em comunidades pra compartilhar experiências, fazer perguntas e se apoiar. Você pode ser o primeiro.

Tire suas dúvidas

Perguntas, dicas e experiências compartilhadas aqui na página

Participe da discussão

Faça login para postar dúvidas, compartilhar experiências e interagir com especialistas.

Fazer login

Doenças relacionadas

Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico

Referências e fontes

Bases de dados externas citadas neste artigo

Publicações científicas

Artigos indexados no PubMed ligados a esta doença no grafo RarasNet — título, periódico e PMID direto da fonte, sem intermediação de IA.

  1. [Recommendations from the GBMHM and the Fi-LMC for the diagnosis and management of chronic myeloid leukemia].
    Bulletin du cancer· 2026· PMID 40908230mais citado
  2. Midostaurin shapes macroclonal and microclonal evolution of FLT3-mutated acute myeloid leukemia.
    Blood advances· 2025· PMID 39418643mais citado
  3. Analysis of peripheral neuropathy in the POLARIX study using clinician- and patient-reported outcomes.
    Blood advances· 2025· PMID 40088467mais citado
  4. Conditional survival of children, adolescents and young adults (0-24 years) diagnosed with leukaemia during 2000-2014 world-wide: (CONCORD-3).
    European journal of cancer (Oxford, England : 1990)· 2025· PMID 40578047mais citado
  5. Survival of European children, adolescents and young adults diagnosed with haematological malignancies in the period 2000-2013: Results from EUROCARE-6, a population-based study.
    European journal of cancer (Oxford, England : 1990)· 2025· PMID 40334304mais citado
  6. A Rare Hybrid Presentation: Coexistence of Necrotizing and Histiocytoid Variants of Sweet Syndrome (SS) in a Patient With Acute Myeloid Leukemia (AML).
    Cureus· 2026· PMID 41994822recente
  7. Multifocal Posterior Pigment Epitheliopathy Complicated by Circumferential Choroidal Detachment Treated With Fluorescein Angiography-Guided Focal Laser Photocoagulation: A Case Report.
    Cureus· 2026· PMID 41994691recente
  8. Case Report: Chronic myeloid leukemia in a 13-year-old-a rare pediatric case of extreme hyperleukocytosis in chronic phase.
    Front Med (Lausanne)· 2026· PMID 41994446recente
  9. Acid ceramidase inhibition enhances BCL-2 targeting in venetoclax-resistant acute myeloid leukemia.
    Blood Neoplasia· 2026· PMID 41994327recente
  10. The interplay between probiotics and mast cells in gut inflammation: a mini-review.
    Front Cell Infect Microbiol· 2026· PMID 41994207recente

Bases de dados e fontes oficiais

Identificadores e referências canônicas usadas para montar este verbete.

  1. ORPHA:171895(Orphanet)
  2. MONDO:0015756(MONDO)
  3. GARD:20130(GARD (NIH))
  4. Variantes catalogadas(ClinVar)
  5. Busca completa no PubMed(PubMed)
  6. Q55785693(Wikidata)

Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.

Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar

Hemopatia mieloide
Compêndio · Raras BR

Hemopatia mieloide

ORPHA:171895 · MONDO:0015756
Medicamentos
9 registrados
MedGen
UMLS
C5680514
Wikidata
DiscussaoAtiva

Nenhuma novidade ainda. O agente esta monitorando.

0membros
0novidades